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ABSTRACT
This study assesses the utility of Ajzen's (1988) Theory of Planned Behaviour
(TPB) in predicting adherence to drug reduction plans in chronic pain patients.
At the beginning of a ten week pain management programme, 40 participants
expressed their attitudes, subjective norms, perceived control and intentions with
respect to drug reduction. A measure of self-efficacy was also used. Twenty-
nine participants opted to work on drug reduction plans and data on adherence
and drug reduction was collected throughout the programme and at 1 and 18
month follow-up. Questionnaires were re-administered following pain
management intervention to assess whether changes in attitudes and self-efficacy
had occurred. Partial support was obtained for the TPB. Attitudes and
subjective norms were found to predict intention to reduce and attitudes and,
surprisingly, negative intention were found to predict actual drug reduction. The
model was unable to explain any of the variance in adherence. It was suggested
that this was due to the patient-controlled nature of drug reduction becoming
confounded with adherence. More support was obtained for the Self-Efficacy
Theory, with this variable predicting adherence, drug reduction and
maintenance. Increases in self-efficacy were observed over the course of the
programme with perceived barriers being the only TPB variable to change over
treatment. Return rates of 100% and 79% were achieved at 1 and 18 month
follow-up respectively. Follow-up at 18 months revealed some relapse in drug
intake and self-efficacy but not back to pre-treatment levels. No relationship
was found between nonadherence to plans and relapse in drug reduction post-
treatment. Participants fell into 3 groups: 24% made no progress after intending
to reduce, 38% made progress but then relapsed to varying extents and 28%
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1. INTRODUCTION
1.1. INTRODUCTION TO CHRONIC PAIN AND ITS TREATMENT
Chronic pain is most usefully defined as pain lasting six months or more (Williams
& Erskine, 1995). It affects over ten per cent of the population and approximately
one per cent are severely disabled (von Korff, Dworkin & Le Lesche, 1990). Often
the causes are not fully understood and tests fail to identify clear-cut pathology. For
many, a wide range of traditional methods of pain relief have failed creating
concerns, in addition to human suffering, of excessive use of health service resources
and lost industrial output.
The chronic pain patient tends towards rest and avoidance of activity leading to a
deteriorated physical state producing further symptoms and multiple losses, eg.
work, income, social life. This contributes to feelings of depression, anxiety and low
self-esteem which adversely affect the pain experience. Many patients enter an
"overactivity-rest" cycle as they try to "catch up" on good days but end up having to
rest for increasingly longer periods. Difficulties can also be perpetuated by the
medical profession with multiple referrals, surgery and excessive drug use often
adding to patients' suffering.
If patients can accept that a cure is unlikely then pain management can help them to
cope with their pain more effectively. A multi-disciplinary cognitive-behavioural
approach is the predominant model. This approach has been well-established in the
USA for some time but has only begun to flourish in the UK over the last ten years,
mainly via outpatient groups. The treatment focuses on the behaviours and beliefs
which exacerbate and maintain pain. Operant and cognitive techniques are used to
increase well behaviours (eg. independent activity) and decrease pain behaviours (eg.
prolonged rest, excessive drug use). A typical pain management programme will
include education, teaching behavioural and cognitive skills, a stretch and exercise
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programme, medication reduction, goal-setting and pacing, relaxation training,
relapse prevention and a family and follow-up session.
Appendix A shows the format of the Astley Ainslie Hospital pain management
programme (AAH PMP), where the present study was carried out. This programme
is run by a multi-disciplinary team including a clinical psychologist, physiotherapist,
nurse, occupational therapist and doctor. It aims to teach effective self-help ways of
managing and coping with chronic pain, to teach a system that allows patients to
resume activities they have given up, to improve quality of life, to increase
confidence, to reduce anxiety and depression, to reduce demands on health service
resources and to increase understanding about pain and maintaining factors. It does
not aim to cure pain. Due to limited understanding about who can be helped,
inclusion criteria are kept to a minimum. The AAH Pain Management Team look
for evidence of disruption to personal and family life, mood changes, a wish to
increase activities and some relief from pain being found from some source. They
exclude those with a major psychiatric illness, where further medical treatment is
indicated or where the applicant wishes to look for medical treatment.
Amanda Williams has been an important contributor to outcome research in the UK.
UK studies of outpatient programmes (eg. Skinner, Erskine, Pearce, Rubenstein,
Taylor & Foster, 1990; Luscombe, Wallace, Williams & Griffiths, 1995) and
inpatient programmes (eg. Williams, Nicholas, Richardson et al., 1993) have
reported significant improvements in such areas as quality of life, physical
performance, depression severity and confidence with the Williams study showing
these to be well-maintained at one and six month follow-up. As expected, pain
intensity was the only measure to show less clear-cut improvements but ratings of
how distressing the patients found the pain showed significant reductions (Skinner et
al., 1990). Williams, Richardson, Nicholas et al. (1996) compared inpatient and
outpatient treatment and found both groups made significant improvements in
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physical performance and psychological function and reduced medication use.
However, inpatients made greater gains and maintained them better at one year.
They noted an inpatient format offers a more intensive programme in a more
consistent operant environment but the costs are around four times that of an
outpatient programme.
Flor, Fydrich & Turk (1992) conducted a meta-analysis of 65 outcome studies and
proclaimed multidisciplinary treatment to be effective and superior to no treatment
or conventional, single discipline approaches. However, a number of common
methodological problems were acknowledged, eg. lack of randomized design, high
rates of attrition at follow-up. Some of these difficulties have been recently
addressed by Morley, Eccleston & Williams (1999). These authors conducted the
first meta-analysis of 25 randomized controlled trials of cognitive behaviour therapy
(CBT) and behaviour therapy for chronic pain. They also concluded that
psychological treatments based on the principle ofCBT are effective. Cognitive
behavioural treatments produced significant effect sizes on all domains of
measurement in comparison to waiting list controls and significantly greater changes
on half the domains measured compared to alternative active treatments, eg. regular
pain clinic attendance, physiotherapy. Morley et al. observed that measurement of
domains with economic importance (eg. health service use, drug intake) and process
variables (eg. adherence to treatment methods, patients' expectations of change) was
generally lacking.
It is still unclear by what therapeutic mechanisms or processes multi-disciplinary
programmes achieve their successful outcomes. Jensen, Turner & Romano (1994a)
observed, in keeping with cognitive-behavioural theory, that changes in pain-related
beliefs and cognitive coping strategies were associated with improvement after
multi-disciplinary treatment. This finding cannot be interpreted as proving a causal
relationship between changes in cognition and improvement. Functioning may
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change as a result of changes in beliefs and coping, beliefs and coping may change as
a result of altered functioning, or all may interact dynamically over time.
Interestingly, changes in some behavioural coping strategies specifically targeted in
multi-disciplinary treatment (eg. exercise, relaxation, decreases in drug use) did not
explain significant amounts of improvement. Consequently, Jensen et al. suggest
that improvement following multi-disciplinary pain treatment may be more closely
associated with changes in what patients think about their pain than what they do
about their condition. However, they note that it could take longer than three to six
months post-treatment for benefits of some of these behavioural coping strategies to
emerge.
The issue of relapse has received little attention in the chronic pain literature.
Despite outcome studies consistently reporting initial improvement in many
individuals, follow-up data suggest that substantial numbers, typically between 30
per cent and 70 per cent of patients attending chronic pain treatment programmes,
relapse over a one year to five year period (Keefe, Gil & Rose, 1986). Dolce,
Crocker & Doleys (1986a) found much treatment efficacy outcome data was
maintained at 6 and 12 months but that significant amounts of relapse had occurred
for medication use and exercising. They reported that 97 per cent of patients in their
sample had been free of analgesic medications at time of discharge but this number
was reduced by almost one third at follow-up. Similarly, Cinciripini & Floreen
(1982) reported a 28 per cent relapse at 6 months and a 39 per cent relapse at 12
months in terms of numbers remaining free of medication. In Cinciripini & Floreen's
study 75 per cent and 65 per cent of questionnaires were returned at 6 and 12 months
respectively. As follow-up studies are based on only those patients who are available
and willing to participate in follow-up assessment they require to be interpreted with
caution.
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Even less is known about the related topic of patient noncompliance to pain
management recommendations which tends to be inferred from outcome. However
a complex relationship exists between compliance and treatment outcome and one
should not be assumed from the other. This study will investigate compliance during
a pain management programme. Lutz, Silbret & Olshan (1983) indicated that
compliance rates are more appropriately assessed within each separate therapeutic
regimen of pain management, as opposed to an overall compliance measure, since
correlations between different behaviours within a regime may be low. Therefore
the component of drug reduction, an area of pain management which evokes
controversy and difficulty, was selected for investigation here.
1.2. DRUG REDUCTION IN PAIN MANAGEMENT PROGRAMMES
A wide variety of drugs are prescribed to chronic pain patients (eg. non-steroidal
anti-inflammatories (NSAIDS), opioid analgesics, antidepressants and
benzodiazepines) despite a lack of evidence that long term use is beneficial
(Spanswick & Main, 1989). For many patients, opiates have proven to be ineffective
in relieving pain and improving function (Pither & Nicholas, 1991) with patients
reporting no increase in pain during drug reduction (eg. Williams et al., 1993).
Furthermore, patients frequently experience unwanted side-effects such as impaired
cognitive function, drowsiness and constipation, reducing their quality of life even
further. Long term consequences include gastric ulcers and liver and kidney
problems.
Despite these disadvantages, many continue to look to analgesics for help in
managing their pain. In this sense, opiate use can be construed as an obstacle to pain
management (Williams, 1993). Drug use may even exacerbate the patients' problems
when consumed on an "as required" (prn) basis, only when pain is severe. Fordyce
(1976) believes this can reinforce pain behaviour since increased pain and pain
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behaviour become associated with (ie. reinforced by) the perceived benefits of pain
relief. Therefore, at the very least, taking analgesics time-contingently rather than
pain-contingently is advisable.
Reduction of pain-related medication and substitution of other strategies, eg.
relaxation, has become an integral part of pain management programmes. The term
"drugs" is used intentionally in preference to "medication" or "pills" in order to
utilize its negative connotations. There are two main methods of reduction which
both involve taking drugs on a time-contingent basis. The first, a staff-controlled
approach using a "drug cocktail" (Fordyce, 1976) is commonly chosen for inpatient
courses. Here the active ingredient is masked in a flavoured syrup while the
concentration is reduced by regular amounts over days or weeks (with the patient
being unaware of the reduction schedule) until the cocktail contains no medication.
In the second approach, Patient-Controlled Reduction (PCR), the patient holds their
own supply of drugs and discusses with a nurse the desired rate of reduction. Plans
are reviewed regularly with large deviations being discussed and plans adjusted as
appropriate. Staff-controlled reduction, in particular, has abstinence as its goal.
However, Turk, Rudy & Sorkin (1993) point out that what constitutes successful
drug reduction may vary between the treatment stakeholders. For example, third
party payers may desire abstinence whilst patients may aim for judicious use.
Patients choose between the two methods on the INPUT inpatient course in London.
An INPUT study, offering this choice, showed that reduction ofNSAIDS and
antidepressants were maintained at one and six month follow-up (Williams et al.,
1993). However, opioid analgesics were reduced following treatment but increased
markedly prior to one month follow-up with little further change at six months when
the mean daily dose was still half that at admission.
A further INPUT study by Ralphs, Williams, Richardson, Pither & Nicholas (1994)
compared the effectiveness of the two methods for opiate reduction. Patients were
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able to choose which method to employ in aiming for complete withdrawal by
discharge. Patients who opted for the cocktail method started at higher morphine
equivalents, were less confident in their ability to cope without medication and rated
their everyday activities as more disrupted by pain. A greater number of the cocktail
group were abstinent at discharge (89 per cent vs. 68 per cent) but this advantage had
disappeared at one month follow-up, with abstinence rates being equivalent for the
two groups (55 per cent) at six months. Furthermore, at this stage, non-abstinent
cocktail group patients were taking significantly larger doses of opiates than PCR
patients. Admission opiate dose level was the best predictor of abstinence at
discharge and of subsequent opiate dose level in non-abstinent patients. It was
suggested that the higher relapse rate with the cocktail method might be due to PCR
patients having developed skills of controlling their own intake in the presence of a
supply. Szymanski, Epstein, Wimberly & Madtes (1979) argue that PCR will
strengthen the maintenance of reduction as patients will attribute progress to their
own behaviour. However, the beliefs of the patients who chose the cocktail method
were likely to be undermining of maintenance of change. Thus replication of this
study with random allocation to the methods would be useful. Whether particular
patients would do better with a particular method would be another useful line of
research.
The Astley Ainslie Hospital programme uses the PCR approach, largely due to the
practical difficulties of employing staff-controlled reduction in an outpatient setting.





The terms adherence and compliance have been used interchangeably to refer to the
degree to which patients carry out the behaviours and treatments recommended by
their practitioners (Sarafino, 1990, p308). Authors (eg. DiMatteo & DiNicola, 1982;
Meichenbaum & Turk, 1987) have argued that compliance suggests the practitioner
using an authoritarian style with the patient obeying passively and reluctantly. Thus
adherence is the more satisfactory term, being used to imply a more active, voluntary
collaborative involvement of the patient. Despite the emphasis at the Astley Ainslie
Hospital programme being on choice and patient participation, the terms adherence
and compliance may be used interchangeably throughout this text.
1.3.2. MEASUREMENT OF ADHERENCE
A wide variety of criteria and measures of adherence have been used by researchers
making comparison across studies difficult. Measures of adherence can be divided
into two main categories of subjective and objective measures. Some of the most
common approaches within both categories will be outlined, with a view to selecting
a suitable measure of adherence to drug reduction plans. In doing so, it should be
noted that it is not uncommon for pain management patients to have access to a
cabinet full of various back-dated medications.
Classification
Adherence and nonadherence are most usefully conceptualized as forming a
continuum rather than as a dichotomous construct, with most people probably
adhering at an "in between" level (Sarafino, 1990, p309). Various forms of
"violation" are possible along this continuum, eg. consumption of too little
medication, too much medication or additional nonplanned medication. Perfect
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adherence may not be necessary in many cases to achieve the desired health benefits,
therefore clear definitions are required about the amount of deviation permitted
from the regimen before the patient is judged to be noncomplianl.
Subjective Measures
(A) Self-Report
Asking patients directly about adherence is the most frequently used measure in
research and clinical practice. This measure is easy to obtain and allows for ongoing
assessment which is important as compliance may vary over time. However,
intentional distortions may occur with responses likely to be biased in a socially
desirable direction (Turk & Rudy, 1991). Unintentional errors, due to
comprehension and memory difficulties for example, may also occur and diary
records have been used in an attempt to reduce these effects. It should be noted that
self-monitoring may enhance adherence by acting as a reminder and encouraging
discussion of adherence difficulties (Sarafino, 1990). Ley's (1988) review found that
patients' reports yield higher absolute estimates of compliance compared to more
objective measures. However he cautiously suggests that patients' report will give
similar results to other methods on relative standing on the compliance dimension.
(B) Professional Assessment
There is much evidence (eg. Mushlin & Appel, 1977) that clinicians cannot readily
detect noncompliance, even when they feel quite certain of the accuracy of their
estimates. Pain management professionals see patients solely in a hospital
environment making it difficult for them to estimate rates of adherence to home-
based work. It is arguable that GP assessment would simply result in GPs
questioning patients about their drug intake. Furthermore, this would be a lime-
consuming and therefore unfeasible task for GPs on a regular basis.
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(C) Independent Observers eg. family, friends
Turk & Rudy (1991) suggest it may also be useful to obtain reports from family or
friends in the natural environment. However, these people are unlikely to be present
at all times when patients take their often frequent medication, hindering true
reporting. During pilot work for the current study, some patients commented that
their medication use was private and had nothing to do with family or friends.
Objective Measures
(A) Behavioural Measures
Pill or quantity accounting is the most common behavioural measure. Patients are
provided with an over-supply of medication and the remaining medication is counted
at a specific time. However, Turk & Rudy (1991) note that pill counts do not
increase the reliability of statements concerning medication compliance
significantly. This is because this method does not guarantee that those missing
were ingested or other sources for prescribed pills were not obtained. Another
disadvantage is the lack of information about the pattern of drug consumption.
(B) Biochemical Indices
Biochemical tests, eg. of blood or urine, can accurately assess recent medication use
(Turk & Rudy, 1991). However urine tests are only sensitive to medication taken
two to three days prior to the test, so would be an inaccurate measure for the full
week between hospital attendances in the present study. Further difficulties arise
due to individual variation in metabolic conditions and because some drugs possess
identical end-products. Finally, high costs and limited practicality and availability
prevent wide-scale usage.
(C) Outcome
Clinical outcome is rarely an adequate measure of adherence since adherence does
not always have a straightforward linear relationship with clinical outcome, ie. there
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are patients who improve without complying and patients who are totally compliant
who do not derive significant benefits. This was demonstrated in Lutz et al.'s (1983)
study of compliance following muitidisciplinary treatment of chronic pain. Despite
very low overall compliance rates, they obtained 37-59 per cent improved status on
various outcome measures. In correlating outcome with self-reports of compliance,
the present study will be able to comment on the appropriateness of using outcome
as a means of assessing adherence to drug reduction plans. It may be that adherence
to formal plans only has a small impact on the actual quantity of drugs reduced.
Therefore, all of the above methods ofmeasuring adherence to drug reduction plans
contain drawbacks. Given ideal resources, self-report would be combined with a
more objective measure.
1.3.3. RATES OF ADHERENCE
Adherence rates to simple medical regimes, eg. taking prescribed medication, have
been estimated to fall between 38 - 58 per cent (Ley, 1976; Sackett & Snow, 1979).
More demanding regimens, such as diet, smoking or exercise programmes, tend to
have even lower adherence rates, eg. eight per cent in one study by Garb & Stunkard
(1974) on diet for weight reduction. Thus prior to entering a pain management
programme adherence of chronic pain patients to their long-term drug therapy is
likely to be low. They are then expected to make extensive life-style changes to be
continued on a regular basis for the rest of their lives.
Lutz et al. (1983) conducted one of the few studies designed specifically to examine
compliance following multidisciplinary treatment of chronic pain. Using patient
self-report, they found only 12.3 per cent of respondents were complying with their
total combination of regimens at an average follow-up of 23.4 months. However,
compliance with individual regimens averaged at 42 per cent and compliance with
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any one regimen was generally unrelated to the probability of complying with other
behaviours. Drug reduction was not one of the five regimens studied but medication
use was included as an outcome measure. Decreased medication use was found to
correlate significantly with adherence to three regimens: (i) physical therapy and
occupational therapy exercises (ii) home treatments eg. electrical stimulation and
(iii) relaxation and/or self-hypnosis exercises. (Progressive ambulation exercises and
use of proper body mechanics were the other two regimens in this study).
1.4. WHY DO PEOPLE ADHERE AND NOT ADHERE?
No studies could be found which investigated predictors of adherence to the drug
reduction component of pain management programmes specifically. In fact little has
been written about variables relating to adherence to chronic pain management
programmes in general, with the majority of work being atheoretical.
Much of chronic pain research has focused on the stage of adjustment to pain and the
coping strategies employed. During the past decade studies have focused
increasingly on cognitive variables (attitudes, beliefs) as possible mediators of
adjustment to intractable pain (eg. Jensen, Turner & Romano, 1991) and numerous
measures of these constructs have been developed (eg. The Pain Beliefs and
Perceptions Inventory (PBPI); Williams & Thorn, 1989). Probably the best
researched instrument has been the Survey of Pain Attitudes (SOPA) which now
assesses seven attitudes eg. the controllability of pain; relations between
emotionality and pain severity; appropriateness of medication for treating pain
(Jensen, Turner, Romano & Lawler, 1994b). Tait & Chibnall (1998) have recently
extended work with this scale by looking for attitude profiles to mediate behaviour
and psychosocial function. They identified four relatively clear attitude clusters
(self-reliant and medically orientated attitudes each with higher and lower
emotionality associated with pain) that were associated with meaningful differences
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in clinical status. Work on coping strategies has shown "catastrophizing" to be
predictive of low treatment gains and poor maintenance (eg. Keefe, Salley &
Lefebvre, 1992).
Other studies have tended to be "data-mining" projects producing a rather muddled
picture and lacking conclusive information about predictors of treatment success and
failure. For example, Painter, Seres & Newman (1980) examined demographic,
incentive, attitude and psychological variables in 25 pain treatment successes and 25
failures. They concluded that the failure group demonstrated less incentive for
maintaining their gains, most ofwhom continued to receive financial compensation
for their pain. Differences in attitudes were also noted, with the failure group more
likely to assume a dependent, passive stance. The groups did not differ on
psychological diagnostic interviews or on the MMPI. Curiously, patients in the
success group rated themselves as significantly more depressed at the time of
admission in comparison to the failure group. More recently, Williams & Erskine
(1995) concluded that there are not yet any consistent predictors of performance in
treatment or afterwards.
1.4.1. CHRONIC PAIN DRUG USAGE: ADDICTION OR COPING STRATEGY?
Looking to models to guide research is likely to prove more useful as the researcher
is provided with a coherent framework for interpreting findings (Johnston, Wright &
Weinman, 1995). One possibility here would be to view chronic pain drug usage as
a form of addiction and obtain guidance from models of addiction. However, on
studying the criteria for Substance Dependence (DSM1V, 1995) a good fit is not
obtained. For instance, the substance dependent client spends much time using the
substance, recovering from its effects, or trying to obtain it. Chronic pain patients
spend little time actually taking their drugs which they can obtain relatively easily
from their GPs. The substance dependent client reduces or abandons important
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work, social or leisure activities because of substance use. In contrast the chronic
pain patient may be forced to abandon such activities due to his or her pain but often
takes drugs with the aim of being able to maintain these activities. In the substance
dependent client the duration of use episodes are often greater than intended whereas
chronic pain patients may stick to a regular dose and be wary of taking more than
recommended dose levels. The chronic pain patient may be less likely then the
substance dependent client to have repeatedly tried without success to control or
reduce his or her substance use. Finally, a key point in substance dependence is the
continued use of the substance despite evidence of the physical and psychological
difficulties it is causing. The chronic pain patient may not experience difficulties in
the short term or be aware of the long term hazards. The latter may be less well
publicised than those of some substances, eg. nicotine, alcohol. Williams & Erskine
(1995) state that it is much more helpful to treat chronic pain drug use as an attempt
at coping rather than as an addiction. They liken analgesic-taking to other pain
coping strategies in that it can be more a response to cognitive and affective factors
rather than to the pain level alone and may worsen rather than improve the situation.
1.4.2. MODELS OF ADHERENCE
Recently adherence research has been guided by various models to explain behaviour
and it may be more useful to look to these general models of adherence for a
framework here. Other "addictive" health behaviours, such as smoking and alcohol
use, have been studied using such models (see below). The major theoretical
orientations will be reviewed briefly but, given the focus of this study, the cognitive
models will be outlined in most detail.
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(A) The Biomedical Model
Leventhal & Cameron (1987) named the approach which looks for individual factors
to explain adherence, the biomedical approach. Much early research was conducted
under the umbrella of this approach which is largely atheoretical. Countless studies
(eg. Belcon, Haynes & Tugwell, 1984) have failed to find demographic or
personality characteristics which are unique to non-compliers. Furthermore,
characteristics of the illness have not been found to be important generally. For
example, Berndt, Maier & Schutz (1993) reported no consistent correlation between
compliance and pain intensity or duration in chronic pain patients. However features
of the treatment regimen have been identified as relevant to compliance. A review
by Masur (1981) found three factors that were consistently associated with decreased
rates of compliance. Firstly, the complexity of the regimen. In Berndt et al.'s (1993)
study of chronic pain patients, polymedication (ie. daily intake of three or more
preparations) was reported to be a fairly reliable factor for predicting
noncompliance. Interestingly, Belcon et al.'s (1984) review of rheumatoid arthritis
studies found no consistent correlation between compliance and drug dose frequency
but as the mean total daily dose increased there was greater variation in the dose
actually taken, ie. as there was more room for error. The other factors identified by
Masur were the degree of behavioural or lifestyle change demanded and the
duration of the therapeutic regimen. Turk & Rudy (1991) noted that as these are all
inherent in pain rehabilitation, chronic pain patients represent a high risk population
with regard to treatment nonadherence. Important interactions may be lost in this
approach when isolated aspects of a regime are examined in this way.
(B) Learning Theories: Operant Conditioning
The principles of learning theory such as Operant Learning Theory (Skinner, 1953)
have been very influential in providing the rationale for behavioural interventions,
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eg. goal-setting, self-monitoring. This approach came into vogue as research shifted
focus to the behaviours needed for compliance. This model attends to the stimuli or
cues that elicit behaviour and the rewards that reinforce the behaviour. One
potential source of reward in chronic pain patients may be compensation payments.
Some studies (eg. Block, Kremer & Gaylor, 1980) have reported that patients
receiving disability payments or compensation are less adherent. However, the
evidence is equivocal with a number of studies failing to find such support (eg.
Mendelsohn, 1986). Williams & Erskine (1995) point out that the discretionary
nature ofmany welfare benefits is similar in financially rewarding increased
disability, but has not been a major focus of research. However these theories fail to
address how cognitions interact with skills training to impact on compliance. High
relapse rates following behavioural programmes (Cinciripini & Floreen, 1982)
suggest that other variables are important.
(C) Knowledge and the Communication Models
Ley (1982) proposed that a substantial amount of the variance in adherence and
satisfaction could be explained by comprehension and memory variables. Important
factors in his model of communication include the transmission of information from
the doctor to the patient, the intelligibility of the doctor's communications and the
ability of the patient to recall medical information. Ley suggested simple techniques
for improving communication, and thus adherence, many of which are incorporated
into pain management programmes, eg. written instructions; increasing the
individual's general knowledge about his or her illness. However, while
comprehension and retention of the treatment regimen is essential for adherence, it is
not sufficient. The patient must also be motivated to act and it may be that education




Various models have focused on cognitions, eg. attitudes, beliefs, knowledge, to
explain and predict health behaviours and outcomes. Several models have
developed within the Expectancy Value approach which assumes that health
behaviours, decisions or intentions will be based on weighing up of the respective
costs and benefits believed to be associated and the likelihood of achieving these
(Johnston et al., 1995). The four principal models that are relevant to the population
under study will now be discussed.
(1) Social Learning Model: Self-Efficacy Theory
Rotter's version of the Social Learning Theory (1966) focuses on the construct of
Locus of Control - a generalized expectancy about whether one's own behaviour or
forces external to oneself control reinforcements. However, it is the second version
of the Social Learning Theory (Bandura, 1977) which is examined in this study and
which has received much attention in both the adherence and pain literature. This
version predicts behaviour using two variables: self-efficacy expectancy (the
expectation that one is sufficiently competent to perform a desired behaviour) and
outcome expectancy (the expectation that a behaviour will lead to particular
consequences). For example, Social Learning Theory would posit that people will
engage in drug reduction if they have the confidence that they can tolerate or
perform the required action to reduce and the understanding that drug reduction will
be of benefit to them. It is argued that given the necessary skills and incentives, it is
an individual's belief about their efficacy which predominantly determines whether a
coping behaviour will be emitted and persisted with in the presence of obstacles and
aversive experiences, eg. painful stimuli.
Bandura postulated that self-efficacy varies along three dimensions: magnitude (ie.
level of task difficulty), generality and strength. He described efficacy expectations
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as being based upon four main sources of information: performance
accomplishments, vicarious observation, verbal persuasion and physiological state.
However, more important is how this information is appraised by the individual.
Despite cognitive variables being the primary determinants of behaviour, techniques
that provide performance-based accomplishments (ie. behavioural experience,
practice) are the most powerful tools for bringing about behaviour change (Bandura,
1982).
Self-efficacy has been found to predict a range of health-related behaviours, eg.
adherence to health recommendations in rheumatoid arthritis patients (Taal, Rasker,
Seydel & Wiegman, 1993). There have been several studies examining the
relationship between self-efficacy and treatment outcome in the chronic pain
population. Nicholas, Wilson & Goyen (1992) found that patients in the cognitive
behaviour therapy/physiotherapy treatment condition for chronic pain improved on
self-efficacy ratings and these were maintained at follow-up. Both Dolce et at.
(1986a) and Kores, Murphy, Rosenthal, Elias & North (1990) have also reported that
chronic pain patients' self-efficacy scores significantly improve with pain
management input. Furthermore, higher post-treatment self-efficacy ratings were
positively related to improved functioning at follow-up (as measured by greater
exercise levels, less medication use and better work status in the Dolce et al. (1986a)
study). Post-treatment self-efficacy was a better predictor of maintenance than pre-
treatment self-efficacy. These studies suggest that self-efficacy expectancies may be
useful predictors of treatment outcome among chronic pain patients. Dolce,
Crocker, Moletteire & Doleys (1986b) suggest that a subgroup of chronic pain
patients exist who fail to display improvements in self-efficacy despite experiencing
behavioural success, ie. they may fail to employ newly acquired management skills
following treatment due to low efficacy beliefs and are consequently good
candidates for relapse. In clinical practice Dolce observed that these patients tend to
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attribute their success to external factors (eg. therapist encouragement/guidance)
rather than their own skills and abilities.
Dolce (1987) outlined three mechanisms of how perceived self-efficacy could bring
relief from pain. First, people who believe they can control pain are likely to
mobilize whatever coping skills they have learned. Second, people who are self-
efficacious may persevere in their efforts. Finally, a sense of self-efficacy may
reduce distressing anticipations that create aversive physiological arousal and bodily
tension which may exacerbate pain sensations and discomfort. Meanwhile, Bandura
and his colleagues attempted to clarify the relationship between self-efficacy and
physiological mechanisms of pain control. Bandura, O'Leary, Taylor, Gauthier &
Gossard (1987) found evidence that attenuation of the impact of pain stimulation by
cognitive means is mediated by both opioid and nonopioid mechanisms. The
stronger the perceived self-efficacy to reduce pain, the greater was the opioid
activation. Pain tolerance was greatest when both mechanisms were present (ie.
cognitive coping and opioid activation). However, cognitive copers were able to
achieve some increase in pain tolerance even when opioid mechanisms were blocked
by an opioid antagonist.
The Pain Self-Efficacy Questionnaire (PSEQ) (Nicholas, 1989) is presently in vogue
in the UK. ft asks patients to rate their confidence in performing an activity whilst in
pain and is therefore more a measure of pain tolerance beliefs (Nicholas, 1994). It
aims to measure the strength and generality of pain sufferers' beliefs and is
disadvantaged by the omission of the third "difficulty" dimension from Bandura's
model, according to Skevington (1995). Data has been collected to demonstrate the
reliability and validity of the instrument (Nicholas, 1994) and its sensitivity to
treatment changes (Nicholas et al., 1992). This 1992 study illustrates that the PSEQ
scores are not simply a reflection ofmood or pain severity.
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However, Dolce et al. (1986a) advocated that self-efficacy ratings are not completely
independent of other predictive measures. Lin & Ward (1996) described a positive
correlation between self-efficacy and perseverance of coping effort in patients with
chronic low back pain and stated that perseverance of coping effort mediated the
effect of self-efficacy on pain outcomes. Similarly, Keefe, Kashikar-Zuck, Robinson
et al. (1997) found that several pain coping strategies (ignoring pain sensations,
coping self-statements and catastrophizing) predicted a significant proportion of the
variance in their patients' (with osteoarthritis or persistent knee pain) ratings of self-
efficacy, after controlling for pain intensity and demographic variables. While a
relationship between efficacy and successful coping has been demonstrated, this
research is correlational and the mechanisms which underlie this relationship could
be reciprocal and remain unclear. Difficulties arise due to the confounding of
different dimensions, eg. coping strategy and outcomes of coping (Williams &
Erskine, 1995). Skevington (1995) also discusses the novelty of the self-efficacy
concept. She argues that ratings of self-efficacy may be no more than statements of
intention (that is decisions to act that are the result of expectations and not
expectations as such) because people are often unable to tell whether their
performance is living up to expectations. This distinction is utilised in the Theory of
Planned Behaviour which will be discussed in 1.4.2.(D)(3).
There has been less research examining the effects of outcome expectancies on
coping behaviour in chronic pain. Lin & Ward (1996) also found that outcome
expectancies were positively correlated with perseverance of coping effort and that
this relationship was not moderated by self-efficacy. They claimed that outcome
expectancies and self-efficacy play equally important roles in coping with low back
pain. However, the majority of studies have been less supportive of outcome
expectancy. Council, Ahern, Follick & Kline (1988) found that beliefs about the
effects of specific body movements on pain were related to observed performance of
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those movements. However, these relationships were not statistically significant
when self-efficacy expectancies were statistically controlled. Furthermore, Jensen et
al. (1991) asked chronic pain patients to rate outcome and self-efficacy expectancies
for eight coping strategies, including avoidance of opioid medication use. There was
support for the self-efficacy theory but beliefs about the consequences of coping
efforts and their interaction with beliefs about capabilities were generally unrelated
to coping. Therefore, from research with chronic pain patients, outcome expectancy
appears, at best, to be associated only weakly with coping behaviour. By way of
explanation, Council et al. (1988) found support for their hypothesis that self-
efficacy expectancies may mediate the relationship between outcome expectancy
and functioning. This fuels critics' arguments that self-efficacy expectancy and
outcome expectancy are ambiguous variables which may not be conceptually distinct
(Lin & Ward, 1996). These results suggest that treatment should emphasize the
actual practice and use of adaptive coping strategies over education about their
outcome.
(2) The Health BeliefModel
The Health Belief Model (HBM) (Becker, 1974) was specifically developed to
explain the various factors influencing preventive health behaviours. The model
asserts that the decision to engage in a particular health behaviour will be determined
by beliefs about perceived susceptibility to the health threat, perceived seriousness of
the health threat, perceived benefit of taking the preventive action and perceived
barriers associated with the action. The decision is triggered by an internal or
external cue (eg. an invitation to attend screening). Recently other beliefs, eg.
efficacy beliefs, and demographic factors have been added to the model.
Much research has been conducted using the HBM or some of its components. The
model has consistently received moderate success, at least in the short term, in
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predicting health behaviours (eg. giving up smoking, reducing alcohol consumption).
Janz & Becker (1984) reviewed 24 studies and found perceived barriers to the
behaviour and perceived susceptibility to the condition to be the strongest predictors.
The model has been extended to predict adherence to medical advice and treatment
in both acutely and chronically ill patients. Becker & Rosenstock's (1984) review of
19 such studies concluded that perceived barriers and benefits were the most
powerful dimensions.
The model has been criticised for being unclear as to the precise way in which the
variables combine to predict behaviour and because the dimensions are not
independent (Marteau, 1995). Furthermore, Weinstein (1987) has suggested that
susceptibility and severity beliefs may not even be considered by the individual,
describing experimental subjects as often having great difficulty in answering
questions about likelihood and severity of a particular health threat. This may be the
case with problems relating to continued drug use in chronic pain patients who have
often had their pain and been on drugs for many years.
(3) Theories of Reasoned Action and Planned Behaviour
The Theory of Reasoned Action (TRA) (Ajzen & Fishbein, 1977), which was
developed by social psychologists, asserts that the primary determinant of behaviour
is the person's intention to perform the behaviour. Intention is in turn seen to be
determined by two sets of attitudes. First, the person's personal attitudes towards the
behaviour, which refers to the extent the person has a favourable or unfavourable
evaluation of the behaviour. Second, the subjective norm, or perceived social
pressure to perform or not perform the behaviour. These two factors are
underpinned by sets of beliefs. For the attitude component these are behavioural
beliefs concerned with the likely outcomes of the behaviour and evaluations of these
outcomes. For the subjective norm component the beliefs are normative beliefs
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which reflect the perceived opinions of key other people about the behaviour and the
person's motivation to comply with these opinions. Demographic variables and
factors associated with a health condition are generally presumed to be antecedent to
attitudes and subjective norms.
However the TRA was only intended to be applied to the prediction of behaviour
under voluntary control. Therefore, Ajzen (1988, 1991) put forward the Theory of
Planned Behaviour (TPB) (see Fig. 1.1) in order to extend the TRA to the prediction
of non-volitional behaviour. Thus the TPB includes an additional component - a
measure of perceived behavioural control - which taps the degree to which the
behaviour is seen to be under the person's control. This measure is similar to
Bandura's (1986) construct of self-efficacy. The set of beliefs underpinning this
Fig. 1.1: Ajzen's (1988) Theory of Planned Behaviour
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component focus on perceived barriers to the behaviour, ie. anticipated impediments
and obstacles. The relative contribution of the different components of this model
will vary from one health behaviour to another.
These models have been less widely applied than the HBM in the health field,
despite seeming to have more explanatory power (Johnston et al., 1995). This may
be due to the development of appropriate measures being time-consuming as new
behaviours have to be assessed for each behaviour and population. The TRA has
successfully predicted significant amounts of the variance in intention and
behaviour in a variety of areas such as drug and alcohol abuse and smoking cessation
(Sheppard, Hartwick & Warshaw, 1988). The addition of the perceived behavioural
control component has been found to make a contribution from various studies in the
health field, eg. weight loss (Schifter & Ajzen, 1985) and problem drinking
(Schlegel, D'Averna, Zanna, DeCourville & Manske, 1992). Madden, Ellen & Ajzen
(1992) and Netemeyer, Burton & Johnston (1991) observed perceived behavioural
control to influence both behavioural intentions and actual behaviour for behaviours
low in perceived control (eg. weight loss) but to influence intentions only for
behaviours high in volitional control (eg. voting). Ajzen (1988) stipulated that the
direct path between perceived behavioural control and behaviour represented the
influence of actual control. However, Pellino (1997) reported that perceived control
over taking analgesics was not related to intentions to use postoperative analgesia
following elective orthopedic surgery. She looked at perceived control over taking
analgesics and perceived control of pain and advocated further study of this complex
area. Due to the inpatient status of her patients postoperatively, Pellino was able to
study the TPB using a subjective and objective measure of behaviour for the first
time. She found intentions to take analgesics did not relate to the actual amount of
medication used but did relate to the subjective report ofmedication use. She
hypothesized that this was due to a major event (surgery with the actual occurrence
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of pain) taking place between the measure of intent and behaviour producing a
change in intentions to take medication.
Recent research has studied some of the theoretical assumptions of the model which
previous researchers have been criticized for taking for granted. Richard, van der
Pligt & de Vries (1995) and Parker, Manstead & Stradling (1995) have suggested
that additional measures of anticipated regret and worry and moral norm can
substantially improve the TPB's power to predict (un)safe sexual behaviours and
commission of driving violations respectively. As drug reduction is less influenced
by emotions than sexual behaviour and is not an antisocial or socially controversial
area, these additional variables are less likely to apply. Elliott, Jobber & Sharp
(1995) reported that overall attitudes can be predicted much more accurately using
personally salient beliefs rather than using only those beliefs which are modally
salient for a given population. However, other researchers have found the benefits of
this cumbersome procedure to be minimal. Giles & Cairns (1995) found partial
support for their suggestion that a multidimensional representation of altitudes (ie.
separate measures of positive and negative beliefs) was more accurate and valid than
a unidimensional system for representing attitudes about blood donation. Drug
reduction is also associated with both positive and negative consequences.
The TPB has been criticized for not taking people's prior experience of the behaviour
into account. Ajzen (1988) argued that the addition of perceived behavioural control
and perceived barriers into the model dealt with this criticism, as the effects of prior
behaviour should be mediated by perceived behavioural control. However, Norman
& Smith (1995) and Bagozzi & Kimmel (1995) claimed that the addition of prior
behaviour had direct effects on intentions and subsequent exercising and dieting
behaviour. In the latter study some predictions were no longer significant after
controlling for past behaviour. However, it should be noted that this study was based
on survey and not experimental methodology.
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Cognitive models are criticized for assuming a causal relationship between
cognitions and behaviour when the influences may be bi-directional or involve other
processes. One of their major drawbacks is their inability to produce complete
explanations of social behaviour due to their overemphasis on attitudes. Cognitions
are only one of the many determinants of behaviour and a wider perspective,
including environmental and cultural influences, is required. Coping skills are not
dealt with except to consider the perceived lack of skills as a barrier. Furthermore,
the models focus on conscious, intentional behaviour and ignore the wide range of
automatic actions (eg. resulting from habit or custom) that make up much of daily
activity. At the level of cognitions, there is a lack of agreement about which are
important in which circumstances. Those measured may not be of particular
importance to the individual who may not be able to describe or accurately rate these
"hidden processes" (Johnston et al., 1995). Finally, there is a lack of standardized
measurement tools making proceeding with and comparing across studies difficult.
(4) "Common Sense" Models
More recently cognitive approaches have responded to some of these criticisms with
"common sense" models attempting to identify patients own representations of their
health and illness threats rather than using experimenter generated concepts. The
Self-Regulation Model (Leventhal & Nerenz, 1985) conceptualizes the individual as
a problem-solver who is attempting to close the gap between his or her current state
and a goal state. Individuals feel motivated to engage in health-protective actions
when they notice actual body symptoms or sensations that could be interpreted as
warning signs of future or current disease threats. Leventhal proposes adaptive
behaviours elicited during a health episode are regulated by: (i) the cognitive
representation of the health threat,eg. beliefs about the identity, cause, consequences
and duration of an illness (ii) action planning or coping (iii) appraisal. Thus this
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model encompasses interacting cognitive, emotional and behavioural aspects of the
situation. People's representations may reflect attitudes about prior illness episodes
which may not necessarily apply to the current episode, eg. beliefs regarding chronic
pain, may be guided by the expectations of conditions being time-limited and
curable.
Despite its appeal, there are two major drawbacks with this model. Firstly, there is a
paucity of supporting data although isolated studies show promise. For example,
Meyer, Leventhal & Gutmann (1985) demonstrated how the illness representations
of hypertensive patients can influence their level of adherence to antihypertensive
medication as well as other ways of coping. Secondly, methodological problems
include an absence of operations to assess specific constructs (Leventhal &
Cameron, 1987) and the need to take multiple measures and then make decisions
about whether variables are independent or dependent measures.
Williams & Thorn (1989) developed The Pain Beliefs and Perceptions Inventory
(PBPI) which attempted to capture patients own conceptualizations of what pain is
and what pain means for them. Their inventory was initially comprised of three
factors: pain stability, pain as a mystery and self-blame. They found that beliefs in
the long duration of pain and the perception of pain as a mystery were associated
with lower compliance (as rated by primary therapists from four disciplines) to
physical therapy and behavioural interventions for pain management.
(E) Process Models
Other authors have stressed the importance of considering adherence as a process.
Prochaska & DiClemente's (1982) Transtheoretical Model ofChange and Marlatt &
Gordon's (1980) Relapse Prevention Model postulate that the choice to begin to
adhere, to continue to do so and to maintain the habit may be influenced by different
factors. However, this study focuses on adherence over a narrow time scale and the
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main group of participants would all be categorized in Prochaska & DiClemente's
"action" stage.
1.4.3. MULTI-MODEL STUDIES OF ADHERENCE
Studies have frequently combined variables from more than one cognitive model to
look for predictors of adherence. As previously stated, no studies investigating
predictors of adherence to drug reduction plans could be found but one cognitive
study looked at adherence to taking medication. Brus, van de Laar, Taal, Rasker &
Wiegman (1999) looked for predictors of adherence to taking Sulphasizine in
rheumatoid arthritis patients. Only self-efficacy regarding the use of this medication
correlated with adherence which, on logistical regression analysis, determined 80 per
cent adherence. No relationship was found between adherence and outcome
expectations, perceived attitudes and perceived support of the social environment,
demographic or disease-related variables or perceived barriers.
Granlund, Brulin, Johansson & Sojka (1998) analysed adherence to a five month
exercise programme in subjects with low back pain. They studied several factors
which are either included in or similar to variables from Self-Efficacy Theory, The
Health BeliefModel, The Theory of Planned Behaviour and The Transtheoretical
Model ofChange. They found a combination of age, perceived lack of time to
exercise (a perceived barrier), expected consequences of not taking action to relieve
the back pain (related to the HBM's "perceived susceptibility") and adherence self-
efficacy resulted in a logistical regression model that correctly identified 96 per cent
of higher adherers and 84 per cent of lower adherers after five months of
participation in the exercise programme. Among the variables studied which were
less useful in predicting higher and lower adherers were outcome expectations and
level and stability of commitment (likened to intention). Expected ability to adhere
to the exercise programme (adherence self-efficacy) was more useful than strength
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of self-efficacy to components of the exercise programme which they hypothesized
could be highly susceptible to beginners' enthusiasm. They viewed their results as
providing partial support for the HBM and obviously conclusions could be drawn
with respect to other models. However, they investigated a large number of
variables (more than those mentioned here) in relation to a relatively small sample
size of 51.
1.5. THE PRESENT STUDY
This study will assess the extent to which the Theory of Planned Behaviour can
explain adherence to drug reduction plans in chronic pain management patients. The
TPB was chosen for testing here as it was felt to have the greatest applicability to
drug reduction of the models reviewed which offered tight specification and
guidelines for scale construction. Furthermore, it has not been widely applied in the
health field and, according to Skevington (1995), needs to be taken seriously in pain
research as one of the best models available. Administration of the PSEQ will
provide standardized information and allow comment on the blurred concepts of
self-efficacy and perceived behavioural control.
Such research is required due to the neglect of the issue of adherence in the growing
field of chronic pain management. Unnecessary drug usage is expensive in human
and material terms and adherence to drug reduction plans is desirable to cost-
conscious healthcare purchasers (in terms of cost of drugs and time in GP
consultation) and individual patients. It is hoped that the findings will lead to
improved methods of helping patients to achieve their desired reduction in drug use.
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1.5.1. HYPOTHESES UNDER INVESTIGATION
Exploring the Measures of Adherence
Adherence will be measured using two methods (see Appendix E) which are
expected to correlate highly, as are the two ways of calculating drug reduction. It is
predicted that adherence to drug reduction plans and amount of drug reduction will
correlate moderately and not highly.
Accounting for the Variance in Adherence and Drug Reduction
Demographic/background factors are not expected to be associated with adherence
to drug reduction plans and amount of drug reduction with the exception of the
complexity of the regimen. The main hypotheses being tested involve the Theory of
Planned Behaviour. It is hypothesized that the variables from the theory (ie.
attitudes, subjective norms, perceived behavioural control and perceived barriers
towards drug reduction), collected prior to the decision to opt in/out of drug
reduction, will predict intention to reduce one's drugs. The same variables, plus
intention to reduce, will then predict the behaviours of (i) deciding to opt into drug
reduction work (ii) adhering to drug reduction plans and (iii) reducing drugs. Self-
efficacy variables (PSEQ and drug SE) are also expected to correlate with adherence
to drug reduction plans and amount of drug reduction. A further hypothesis involves
a Decisional Balance variable (TPB Questionnaire Q12). It is predicted that those
who feel the advantages of taking drugs outweigh the disadvantages will be less
likely to adhere to reduction plans and reduce their drugs.
Change During the Programme
The TPB variables and the Decisional Balance variable are expected to become more
favourable towards drug reduction over the course of the programme in those who
opt into drug reduction work. Increases in self-efficacy variables (PSEQ and drug
SE) are also predicted over the course of the programme. These changes are
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predicted on the basis of pain management input and positive experiences of drug
reduction.
Maintenance ofChange
Self-efficacy variables and drug intake scores are expected to show some relapse (as
defined in 4.5) at 1 and 18 month follow-up. It is predicted that nonadherence
during the group will be related to relapse at 1 and 1 8 month follow-up due to
nonadherers failing to learn strategies for dealing with setbacks or trying to reduce
too much too soon. Finally, self-efficacy variables will be associated with
maintenance at 1 and 18 month follow-up with post-treatment SE being a better
predictor than pre-treatment SE.
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2. METHODOLOGY
Approval for this study was sought and obtained from the Lothian Area Ethies of
Medical Research Committee.
2.1. DESIGN
A prospective, naturalistic design was employed with patients deciding whether to
opt in or out of drug reduction. The study used a standardised questionnaire format.
2.2. SETTING
The setting is the Health Psychology Department, Astley Ainslie Hospital,
Edinburgh. Its PMP consists of a 12 session multidisciplinary cognitive-behavioural
approach to the outpatient treatment of chronic pain over ten weeks. It is aimed at
controlling pain as opposed to curing it. The AAH is representative ofmajor
outpatient clinics in its scope and structure (see Appendix A). On the third session,
the doctor held an education session which explored the use of medication in chronic
pain and strongly recommended the desirability of drug reduction as part of the PMP.
2.3. SUBJECTS
Subjects were taken from a consecutive series of patients attending the AAHPMP
between October 1995 and April 1996. Inclusion and exclusion criteria for the
AAHPMP are presented in 1.1. All those who were taking pain-related medication




TPB variables as applicable to pain-related drug reduction were measured using the
TPB Questionnaire. This measure was designed by the author specifically for the
present study (see 2.5.1.).
(A) Questionnaire (Long Form) (See Appendix B)
The long form of the questionnaire contained the following measures. Unless
otherwise stated, all items were rated on seven-point Likert scales with scores
ranging from one to seven.
Attitudes
Attitudes were measured in two ways. The concept "drug reduction" was rated on
three bipolar adjective scales which were summed to provide a direct measure of
attitude (Q23-25). For the second measure, the belief strength associated with ten
possible positive and negative consequences of drug reduction was assessed (Ql-10)
and evaluations of each of the ten possible consequences were obtained (Q13-22).
Five clinical psychologists were asked to indicate whether agreement or
disagreement with the beliefs was likely to predict drug reduction and whether most
people with pain would be likely to think the consequence good or bad. Mixed
responses were obtained for three items (Q4, 5 &9) which were consequently
omitted from the data set. The products of the remaining seven items were then
summed to produce a belief-based measure of attitude.
Subjective Norms
Subjects indicated their beliefs that each of three referents (if applicable) would
approve or disapprove of their reducing their drugs on a scale ranging from -3 to +3
(Q28-30) and their motivations to comply with each referent (Q32-34). The products
of these ratings were summed to produce a belief-based measure of subjective norm.
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Perceived Behavioural Control (PBC)
Two measures ofPBC were obtained. The first measure of PBC required subjects to
indicate how likely 12 factors would be in preventing them from reducing their drugs
(Q35(a)-(1)) with responses being summed to produce the Perceived Barriers score.
A second, more direct measure, was obtained by assessing the degree to which
subjects believed they had control over reducing their drugs (Qs26 & 31) and their
self-efficacy to reduce, using Q7 of the PSEQ (see 2.4.2.) to avoid repetition, with
responses to these three items being summed.
Intention
Intention was assessed by one item(Q27) dealing with the likelihood of drug
reduction.
Decisional Balance
In addition to the TPB items, subjects were asked to respond 'yes' or 'no' as to
whether the advantages of taking drugs for their pain outweighed the disadvantages
(Q12).
(B) Questionnaire (Short Form) (See Appendix C)
The short form of the questionnaire repeated the items for attitudes (excluding
evaluations), PBC and the decisional balance question. The tense was altered for the
perceived barriers items. In addition, subjects were asked how much support they
got on the course to help them reduce their drugs (Q20).
2.4.2. PAIN SELF-EFFICACY QUESTIONNAIRE
Confidence in performing a range of roles and activities despite the pain was
measured using the PSEQ (Nicholas, 1989) (see Appendix D).
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2 4.3. ADHERENCE
Self-report measures of adherence to drug reduction plans were calculated from
weekly recording sheets (see Appendix E for method of calculation).
2.4.4. DRUG REDUCTION
Drug reduction scores were calculated by comparing the final week recording sheets




The questionnaire to assess the TPB variables as applicable to pain-related drug
reduction was devised by referring to studies which had used this model to test other
behaviours and by interviewing chronic pain patients and pain management staff to
identify key issues relating to drug reduction. Four patients and four members of
staff were asked to list the advantages and disadvantages of reducing pain-related
medication, the people who might approve or disapprove of reduction and the factors
that might help or prevent reduction. Responses to these questions were used to
develop behavioural, normative and control belief items respectively.
The provisional questionnaire was piloted on four chronic pain patients and was read
by four members of the pain management team who were asked for comments. This
process resulted in the finalized questionnaire. As pilot work was limited due to
time constraints, the finalized questionnaire included two open-ended questions




At the session following the medication education session, subjects taking pain-
related medication who had agreed to participate completed the TPB and PSEQ
questionnaires (Time 1). Questionnaires were completed during the session in the
presence of the experimenter. Following questionnaire completion patients met
individually with the nurse who oversees drug reduction. Initial details of drug
intake were recorded and it was ascertained whether the patient wished to work on
drug reduction.
Those opting to work on drug reduction plans met the nurse on a weekly basis to
review and specify their plan for the forthcoming week, and monitored their daily
medication use on a drug recording sheet designed specifically for the study (see
Appendix F/G). At discharge from the group (Time 2), all subjects who were on
pain-related medication at Time 1 (including those who had opted in and out of drug
reduction work) completed the short form of the TPB questionnaire and the PSEQ.
The group who had opted into working on drug reduction plans during the
programme were followed up by post at 1 month (Time 3) and 18 months (Time 4).
They completed the PSEQ and a record of their drug intake over one week. Subjects
who failed to respond within three weeks were contacted by telephone and
encouraged to return the information or provide it verbally over the telephone.
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3. RESULTS
The main data analysis was conducted using SPSS for Windows: Version 6. Version
7 was used to analyse the 18 month follow-up data. Throughout the results section
significance levels have been coded in the tables as follows: * = p<0.05,
** = p<0.01, *** = p<0.001.
3.1. DESCRIPTION OF THE SAMPLE AND THE DATA SET
3.1.1. CHARACTERISTICS OF THE PATIENTS IN THIS STUDY
Of 60 patients attending six groups during the period of study, 45 subjects were
taking regular pain-related medication. Fig. 3.1 illustrates behaviour over the course
of the group for these 45 subjects. Data from the two patients who dropped out of the
programme after opting into drug reduction was not examined due to the small drop
out rate. No patients dropped out of the research but continued to attend the group.
At one month follow-up (Time 3) a 100 per cent return rate was achieved from the
29 subjects who had opted into drug reduction. Details of these 29 patients (ie. the
main group on which analysis was conducted) are provided in Table 3.1. The
majority (23) had back pain (with nine of these suffering additional pains), three had
neck/shoulder pain, one had abdominal pain, one had leg pain and one had pain all
over.
Table 3.1 provides demographic and other background information for patients in
this study who opted into drug reduction and patients from a large INPUT evaluation
study (Williams et al., 1993) in order to establish how far the current patients are
representative of the chronic pain population. This data is collected routinely at the
start of the AAH PMP, with the exception of the self-efficacy scores which were
collected as part of the present study. The current sample was slightly younger and
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Fig. 3.1: Flow chart of subject behaviour
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Table 3.1: Demographic/background characteristics for current and comparison
samples
Sex (% female)
Current "opting in" sample INPUT sample*
(n=29) (n=212)
83 65
Mean SD Range Mean SD Range
Age (Years) 43.9 12.7 23-74 50.0 13.3 20-84
Years in pain 12.5 10.7 1-35 10.5 9.9 1-47
Dysfunction score (SIP) (%) 64.7 14.2 28.4 11.4
Depression score 10.4 3.6 (HAD) 18.5 8.7 (BDI)
Self-efficacy score (PSEQ) 23.0 8.0 24.1 11.4
n prior to drop outs 31 243
% dropped out 6 9
SIP = Sickness Impact Profile (AAH = short form, INPUT == long form)
HAD = Hospital Anxiety and Depression Scale (range 0-21)
BDI = Beck Depression Inventory (range 0-63)
PSEQ = Pain Self-Efficacy Questionnaire (range 0-60)
* Williams et al. (1993)
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contained markedly more females than the INPUT group. Duration of pain,
depression scores, self-efficacy scores and drop out rates are similar for this sample
and the INPUT programme (with Hospital Anxiety and Depression Scale (Zigmond
& Snaith, 1983) and Beck Depression Inventory (Beck, Ward, Mendelsohn, Mock &
Erbaugh, 1961) means both representing mild depression). Unfortunately, the long
form of the Sickness Impact Profile (Bergner, Babbit, Carter & Gilson, 1981) and the
short form (Roland & Morris, 1983) are not directly comparable. Therefore,
conclusions about differences in self-reported dysfunction in the two samples cannot
be made.
3.1.2. MISSING QUESTIONNAIRES AND MISSING DATA
One subject failed to complete the Self-Efficacy questionnaire at Time 2. The
specific item relating to medication use (Q7) was replaced with the overall series
mean.
The TPB questionnaires of one subject were judged inadequate for use. This man,
who was known to abuse alcohol, responded by circling "7" for the vast majority of
items whilst frequently placing ticks at the opposite end of the scale. It was decided
to remove him from the main analysis. His Self-Efficacy questionnaires were judged
to be satisfactory for inclusion.
Only one question (TPB questionnaire Time 2, Q18(h)) was omitted by one subject.
The missing value was replaced with the overall series mean.
The TPB questionnaire required subjects to provide normative opinion regarding
their hospital consultant if applicable on a scale of -3 (disapprove) to 3 (approve).
20 of the 29 subjects had a current hospital consultant. Those without were given a
score of 0 on the basis that no such person existed to provide either an approving or
disapproving influence.
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3.2. EXPLORING THE DATA
Exploration of the data was based on the sample who opted to work on drug
reduction for which parametric analysis was planned (n=28).
3.2.1. THE FREQUENCY DISTRIBUTIONS OF THE VARIABLES
The frequency distributions of the main variables being studied were examined in
order to determine how far they approximated a normal curve and therefore met the
assumptions of parametric statistics. In most cases the sample distributions did not
differ substantially from normal. The exceptions were the subjective norms and
PBC scores. Scores on these variables were clustered around one end of the scale
and more items would be required to adequately differentiate the participants. It was
therefore felt that transformation of the data was unlikely to help. Summary data is
presented in Table 3.2.
3.2.2. FURTHER EXPLORATION OF THE NEWLY DEVISED
QUESTIONNAIRE
Responses to the open-ended questions, designed to pick up any missed concepts,
suggest that most ideas were covered by the questionnaire. Two subjects mentioned
"becoming more angry or bad-tempered" as an additional consequence of reducing
and "cold and damp weather conditions" was suggested as a barrier which had not
been included. Of course other important consequences/barriers may exist which the
subjects either could not write down (due to lack of awareness) or chose not to write
down (eg. because to do so would require effort or personal disclosure). However,
an open-ended question was not used to check the subjective norms measure and
opinions of other people not included in the questionnaire (eg. employers, friends,
pain management group members and staff) may be influential. Employers (where
applicable) may have strong views about their employees taking medication to
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Table 3.2: Comparison of subjects opting in and out of drug reduction
Age














Intention 4.29 1.80 2-6 5.11 1 .42 2-7
Attitudes (direct) 13.14 4.56 7-20 16.14 4 .04 9-21
Attitudes (belief-based) 22.14 9.12 10-37 27.89 6 .80 16-45
Subjective Norms 1.29 3.09 -2-6 4.04 3..52 -2-9
PBC 12.29 5.79 3-18 14.36 2..77 9-19
Perceived Barriers 41.14 6.01 29-46 48.21 9..48 34-70
SE VARIABLES
PSEQ Total 25.43 6.40 17-35 23.04 8 .01 8-45
Drug SE (Q7) 1.43 1.40 0-3 1.79 1. o oc 0-4
TIME 2:
TPB VARIABLES*
Attitudes (direct) 12.00 5.66 4-21 16.54 4.01 8-21
Attitudes (belief-based) 23.29 7.34 15-38 29.25 6.51 5-45
PBC 12.71 4.39 6-20 15.02 3.34 7-20
Perceived Barriers 45.00 18.32 21-76 56.87 13.09 25-84
SE VARIABLES**
PSEQ Total 30.00 13.49 5-44 31.43 12.24 10-55
Drug SE (Q7) 2.00 1.53 0-5 2.64 1.93 0-6
OUTCOME VARIABLES:
Compliance (Days) 72.79 24.25 28-100
Compliance (Pills) 87.19 19.37 0-100
Drug Reduction (Excl. tlare-up days) 0.48 0.59 -0.22-2.50
Drug Reduction (Incl. flare-up days) 0.40 0.54 -0.27-1.85
* n=28 (1 TPBquestionnaire judged inadequate)
** n=28 (1 SE questionnaire not completed)
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facilitate work and overactivity or about reducing medication to decrease side-
effects.
Due to the limited time available for the pilot phase, the newly devised TPB
questionnaire could not be validated before the study. However, some attempts were
made to check the reliability after the study had been completed. There
is a lack of existing measures available from which to assess the concurrent validity
of the new questionnaire.
Firstly, the internal consistency was examined using Cronbach's alpha coefficient of
reliability. This was calculated for the two variables consisting ofmore than three
items using the Time 1 questionnaires (n=28). An alpha coefficient of 0.61 was
obtained for the summed belief-based attitudes score and 0.67 for the perceived
barriers score. No individual items were negatively correlated with the variable
total. These coefficients demonstrate that internal consistency is just acceptable for
the two variables tested.
On examining the correlations between the variables one would expect the direct and
indirect measures of attitude and the direct and indirect measures of PBC to be more
closely correlated with each other compared to the other variables. Table 3.3 shows
that the attitude scores are correlating reasonably well with each other, although they
are correlating equally well with intention and perceived barriers. Ofmore concern
is the lack of correlation between the two measures of PBC. Furthermore, the PBC
total does not correlate significantly with the other variables in the model.
The predictive validity of the questionnaire will be assessed later in the results
section.
42









































3 2.3. FURTHER EXPLORATION OF THE MEASURES OF ADHERENCE
Measures of adherence were calculated using the days method and the pills method.
Drug reduction was calculated including and excluding days in flare-up in the week
of discharge (see Appendix E). Mean scores are presented in Table 3.2.
In the absence of an observation method or similar studies enabling comparison of
adherence scores, the measures of adherence were validated by correlating the
various methods employed. Table 3.4 shows a highly significant correlation between
the two direct measures of adherence (r = 0.69, p<().()01, 1 tailed). The days
measure was selected as the primary measure of compliance for use in future
correlations and in the main analysis for reasons outlined in Appendix E and because
the scores better approximate a normal curve and do not contain an outlier.
As one would expect, the scores calculating drug reduction with and without
leniency to flare-up are very highly correlated (r = 0.97, p<0.001, 1 tailed) (Table
3.4). The score excluding days in flare-up was selected as the primary measure of
drug reduction for use in future correlations and in the main analysis in keeping with
the policy implemented when calculating the measures of adherence.
Outcome (ie. drug reduction) is often used as a crude measure of adherence and the
direct measures of adherence were expected to correlate moderately, rather than
strongly, with the drug reduction scores. No correlation was observed. However the
scores in brackets are consistent with this hypothesis. These were obtained on
removing the subject who abuses alcohol (who achieved the largest reduction whilst
being noncompliantj from all the correlations and an outlier (who was not following
group principles) from the compliance (pills method) correlations.
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3.3. COMPARISON OF SUBJECTS OPTING IN AND OUT OF DRUG
REDUCTION
There were seven people in the study who were taking drugs but who opted out of
working on drug reduction plans. Due to the small number these data will not be
tested statistically and the following description is based on impression only. Study
ofTable 3.2 shows that the means for those opting in and out of drug reduction differ
in the expected direction for all the TPB variables, ie. more favourable towards drug
reduction in those who opted to work on drug reduction plans. However PSEQ was
greater in those opting out suggesting a generally low pain self-efficacy is not the
reason for their decision to opt out of drug reduction. As expected there is little
change in the TPB variables between Times 1 and 2 in the group opting out, with the
exception of a small increase in perceived barriers. The SE measures show an
increase between Times 1 and 2.
3.4. ACCOUNTING FOR THE VARIANCE IN ADHERENCE AND DRUG
REDUCTION
3.4.1. DEMOGRAPHIC AND BACKGROUND VAR1ABEES
Table 3.5 illustrates that, as hypothesized, demographic variables (age, sex) and
illness characteristics (self-reported dysfunction (SIP), duration of pain) were not
significantly associated with compliance or drug reduction. Masur (1981)
demonstrated that adherence decreases with the complexity of the regimen, however
number of drugs and adherence were not significantly correlated here.
A significant association was found between higher pre-treatment HADS Depression
scores and lower compliance (r = -0.43, p<0.05, 2 tailed) but not between these
scores and drug reduction. Subjects were asked at the end of the group how much
support they had received on the course to help them reduce their drugs on a scale of
one (none at all) to seven (very much). Their responses ranged from four to seven
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Table 3.4: Pearson's product moment correlations amongst measures of compliance -
1 tailed sig. (n=29)
Measure 12 3 4
1. Compliance,
(Days method)
2. Compliance, Q £,9*** -
(Pills method) (0.81***)
3. Drug reduction, 0.15 0.06 _
(Excluding flare-up) (0.43*) (0.35*)
4. Drug reduction, 0.23 0.05 Q 97***
(Including flare-up) (0.44*) (0.31) (0.98***)
Scores in brackets n=28. Note n=27 for measure 3 (see text for explanation).
Table 3.5: Pearson's product moment correlations between demographic/





Duration of pain -0.22 0.31
HADS - Anxiety -0.11 0.27
HADS - Depression -0.43* -0.07
No. of different drugs -0.24 -0.06
Perceived support 0.26 0.45*
Table 3.6: Pearson's product moment correlations between variable choices and
dependent variables - 1 tailed sig. (n=28)
Intention Compliance Drug Reduction
Summed Beliefs 0.57** 0.23 0.33*
Beliefs x Evaluations 0.61*** 0.07 0.30
Summed Subjective Norms 0.58*** 0.13 0.22
Subjective Norms x Evaluations 0.47** 0.09 0.12
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with an average of 6.1 indicating that all subjects at least felt obliged to report that
they had received adequate-good support. A significant correlation was obtained
between perceived level of support and drug reduction (r = 0.45, p<0.05, 2 tailed).
Group attendance was not examined as little variance was observed in attendance
with the vast majority of subjects who did not drop out attending 11 or 12 sessions.
3.4.2. TPB VARIABLES
Selection of Independent Variables
Several studies (eg. Chassin, Presson, Sherman, Corty & Olshavsky, 1984) have
indicated that using the simple sum of attitudinal and normative beliefs is as
successful in predicting behaviour as the multiplicative scores (ie. beliefs x
evaluations). The summed and multiplicative totals from the present study were
correlated with the dependent variables and are presented in Table 3.6.
On examining the correlations it was decided to use the simple summed normative
beliefs measure in the multiple regression analyses. Likewise the simple summed
beliefs measure was the preferred belief-based measure of attitude. In order to keep
the number of independent variables as low as possible, the significantly correlated
direct and belief-based measures of attitude (r = 0.48, p<0.01, 1 tailed) were
combined to provide one measure of attitude (see Table 3.3). A decision was made
not to sum the two measures of PBC (PBC and perceived barriers) due to the lack of
significant correlation between these variables.
(A) Accounting for the Variance in Intention
Table 3.7 shows that intention to reduce drugs correlated significantly with
attitude, subjective norm and perceived barriers. No association was obtained for
PBC with intention. In order to assess the predictive value of these components on
intention in more detail a multiple regression analysis was conducted on the data.
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Attitudes, subjective norms, PBC and perceived barriers were entered in one step in
keeping with the TPB. This resulted in these variables explaining 65 per cent of the
variance. (Total equation. Ad R Sqd = 0.65, F = 13.29, df = 4,23, p<0.001)
Attitudes (beta = 0.67, p<0.001) and subjective norms (beta = 0.28, p<0.05) made
independent contributions to the prediction of intention (see Fig. 3.2 and Appendix
H).
(B) Accounting for the Variance in Adherence
One can see in Table 3.8 that intention and perceived barriers are weakly but not
significantly correlated with compliance to drug reduction plans. No association was
found for attitudes, subjective norms or PBC. A hierarchical regression analysis was
performed to examine ability to account for compliance. In accordance with the
model, intention was entered on the first step, PBC and perceived barriers on the
second step and attitudes and subjective norms on the third step. The results of the
multiple regression revealed no significant effects and none of the variance was
explained (see Appendix H).
(C) Accounting for the Variance in Drug Reduction
On analyzing drug reduction, Table 3.8 shows that perceived barriers was the best
single predictor of the amount of drugs reduced over the programme. Attitudes also
correlated significantly with drug reduction, but the weak correlation with subjective
norms was not significant. No correlation was observed for intention or PBC. A
hierarchical regression analysis was performed to examine the ability of these
variables to account for drug reduction with the variables entered in three steps as
above. The intention measure accounted for none of the variance in drug reduction.
The addition of PBC and perceived barriers accounted for 13 per cent of the
variance, with only perceived barriers (beta = 0.49, p<0.05) making a significant
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Table 3.7: Correlations among TPB variables entered in MRA - 1 tailed sig. (n=28)
Variable 12 3 4
1. Attitudes
2.Subjective Norms 0.44*
3. PBC 0.03 0.06
4. Perceived Barriers 0.54** 0.25 0.11
5. Intention 0.78*** 0.58** 0.19 0.42*
Table 3.8: Correlations between TPB Variables and Compliance/Drug Reduction
entered in MRA - 1 tailed sig. (n=28)
Compliance Drug Reduction
Attitudes 0.13 0.34*
Subjective Norms 0.13 0.22
PBC 0.09 0.15
Perceived Barriers 0.21 0.44*
Intention 0.21 0.06
Table 3.9: Pearson's product moment correlations between Self-Efficacy and
dependent variables (n=28)
Intention Compliance Drug Reduction
Total PSEQ 0.12 0.38* 0.41*
Drug SE (Q7) 0.30 0.16 0.04
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Fig. 3.2: TPB variables contributing to prediction of intention
Fig. 3.3: TPB variables contributing to prediction of drug reduction
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contribution to the equation at this stage. The addition of attitudes and subjective
norms increased the amount of variance explained by 14 per cent bringing the total
amount of variance explained to 27 per cent. When all the variables were entered,
the analysis revealed a significant negative effect of intention (beta = -0.78, p<0.05)
with attitudes (beta = 0.64, p<0.05) making a positive contribution to the final
equation (see Fig. 3.3 and Appendix H).
The ability of each equation to meet the assumptions of multiple regression analysis
was investigated. Since some of the independent variables were inter-correlated it
was important to assess the impact ofmulticollinearity. On doing so no tolerance
levels were found to be unacceptably small. Furthermore, a random pattern was
observed on plotting the standardised residuals against the predicted residuals
increasing confidence in the results.
3.4.3. SELF-F.FFICACY VARIABLES
Question 7 (Drug self-efficacy) had the lowest mean score of 1.8 on the PSEQ and
lowest item-total correlation of 0.34. Therefore the patients confidence in being able
to cope with their pain without medication was low and was only weakly related to
their general PSEQ score.
In order to assess the contribution of the self-efficacy variables, specific drug self-
efficacy (DSE) and general pain self-efficacy (PSEQ) were correlated with intention
to reduce, compliance with drug reduction plans and amount of drug reduction.
Table 3.9 indicates that DSE at Time 1 is a better predictor of intention than PSEQ
but PSEQ is a better predictor of compliance and drug reduction than DSE.
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3.4.4. DECISIONAL BALANCE VARIABLE
21 of the 29 subjects felt that the advantages of taking drugs outweighed the
disadvantages. No correlation was found between the decisional balance type
question (TPB questionnaire Q12) and compliance (0.06) or drug reduction(0.07).
3.5. CHANGE DURING PROGRAMME
3.5.1. TPB VARIABLES
In order to see if the variables in the TPB became more favourable towards drug
reduction over the course of the group, t-tests were conducted on the data. Table
3.10 indicates that there was no change in attitudes or PBC between the beginning
and end of the group. A significant change in the perceived barriers measure was
observed (t = -3.59, df= 27, p<0.01, I tailed). However, the tense of this question
was changed between the Time 1 and 2 questionnaires. The Time 1 questionnaire
asked "How likely are the following to prevent you from reducing your drugs?" and
the Time 2 questionnaire read "How much did the following prevent you from
reducing your drugs?". Therefore the change obtained represents a decrease between
initial prediction of barriers and actual report of barriers at discharge.
In order to see which individual barriers changed significantly Table 3.10 reports t-
tests conducted on the individual items. A significant decrease between initial
prediction and actual report was obtained for eight of the perceived barriers with the
other four items showing no change.
3.5.2. SELF-EFFICACY VARIABLES
T-tests were also carried out on the SE measures in order to see if there had been an
increase in these scores over the course of the group. Table 3.10 indicates that there
was weak evidence of an increase in the Drug SE between Times 1 and 2 (t = -2.31,
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Table 3.10: T-tests of changes over time
T-tests of changes between Time 1 and Time 2-1 tailed sig.
TIME 1 TIME 2
Mean SD Mean SD t
TPB VARIABLES (n=28)
Attitudes (direct) 16.14 4.04 16.54 4.01 -0.70
Attitudes (belief-based) 27.89 6.80 29.25 6.51 -1.43
PBC 14.36 2.77 15.02 3.34 -0.93
Perceived Barriers 48.21 9.48 56.87 13.09 -3.59**
Individual
Perceived barriers
(a) pain tlare-up 2.64 1.66 3.68 2.04 -2.89**
(b) stress 3.82 1.70 4.64 1.52 -2.35*
(c) low mood 3.79 1.77 4.68 1.70 -2.20*
(d) new pain/injury 3.54 1.71 4.96 1.40 -4 21 ***
(e) do less 3.57 1.77 4.46 1.64 -2.16*
(f) low confidence 4.43 1.50 5.21 1.42 -2.35*
(g) little time/energy 4.18 1.49 5.29 1.21 -3.67***
(h) something new 4.86 1.63 5.40 1.50 -1.77*
(i) pressure from family 5.50 1.50 5.61 1.55 -0.28
(j) poor sleep 3.29 2.02 3.82 1.83 -1.21
(k) withdrawal effects 4.32 1.93 4.71 1.74 -LOO
(1) conflicting advice 4.29 1.54 4.39 1.57 -0.38
SE VARIABLES
PSEQ Total (n=28) 23.36 7.94 31.43 12.24 _4 47***
Drug SE (Q7) (n=29) 1.79 1.08 2.64 1.93 -2.31*
T-tests of changes between Time 2 and Time 3-2 tailed sig.
TIME 2 TIME 3
SE VARIABLES
PSEQ Total (n=28) 31.43 12.24 31.64 13.28 -0.16
Drug SE (Q7) (n=29) 2.64 1.93 2.34 2.09 1.01
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df= 28, p<0.05, 1 tailed) and strong evidence of an increase in Pain SE over the
same period (t = -4.47, df= 27, p<0.001, 1 tailed).
In order to examine the role of drug reduction in accounting for these increases, drug
reduction was correlated with change in SE. Table 3.11 shows that increases in SE
were not associated with experiences of drug reduction.
3.5.3. DECISIONAL BALANCE VARIABLE
Exactly the same number of subjects (21 out of 29) felt that the advantages of taking
drugs outweighed the disadvantages at the end of the group as the beginning.
However, eight subjects (mainly unexpected to the author) had changed their
answers from Time 1.
3.5.4. DRUG INTAKE SCORES
During the programme 22 of the participants reduced their drugs, five did not alter
their intake and two increased their drugs. Three of the 22 who had made reductions
became medication free (two during the course and one during the first month of
follow-up). Table 3.2 illustrates the range of scores on the drug reduction measure
(see Appendix E). Referring to the case descriptions in 3.8 will help to put these
scores into context. Drug reduction scores were 0.9 (John), 0.75 (Jean), 2.5 (Brian)
and 0.0 (Janet).
3.6. MAINTENANCE OF CHANGE: ONE MONTH FOLLOW-UP
At one month follow-up data was collected on drug intake and SE from 100 per cent
of the 29 reducing subjects. Drug intake records were not used for one subject for
whom the follow-up week had been extremely atypical.
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3 6 1. SELF-EFFICACY SCORES
In order to test the hypothesis that SE scores would show some relapse over the one
month follow-up period, t-tests were carried out. Results are shown in Table 3.10.
The results indicate no change in either DSE or PSEQ over the follow-up period.
Thus the improvements made on the SE measures during the group were maintained
at one month follow-up.
3.6.2. DRUG INTAKE SCORES
During the programme seven of the 29 participants failed to reduce their drugs after
planning to do so. The issue of relapse is pertinent to the remaining 22 participants
who made a reduction. Nineteen of these 22 provided information at follow-up and
will be categorized here.
Relapse is defined at this stage as any increase in drug intake between the end of
treatment and one month follow-up. By comparing the weekly records of drug
intake which were completed at one month follow-up with the end of programme
recording sheets, subjects were categorized as "maintainers of abstinence",
"maintainers of partial reduction" (both no change over follow-up), "reducers
following partial reduction" (a decrease over follow-up) and "relapsers" (an increase
over follow-up). The original method of calculating drug reduction (see Appendix
E) was used except "change in dose over one month follow-up" was the numerator in
the equation. Those with increases/decreases of less than 0.1 were categorized as
maintainers with the exception of one subject, whose reduction was small due to an
overall low intake, who was classed as a reducer. In keeping with previous policy
odd days in flare-up were omitted. This led to seven subjects being classed as
maintainers of partial reduction, six as relapsers and there were four reducers. Of the
two participants who had reduced to zero during the group, both were maintainers of
abstinence.
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3.6.3. RELATIONSHIP BETWEEN RHLAPSR AND NONADHERENCE
It was hypothesized that those who were nonadherers during the programme would
be more likely to relapse than the adherers due to failing to learn strategies for
dealing with setbacks or trying to reduce too much too soon. To explore this
hypothesis the group was split into adherers and nonadherers on the basis of the
natural division observed on the compliance (days method) graph (see Appendix I)
ie. <65 = nonadherence and >75 = adherence. For those who had made a reduction
during the programme and for whom follow-up data was available, this division
resulted in 15 compilers and four noncompliers. Follow-up behaviour is provided
for these two groups in Table 3.12.
A Chi-squared Test for Independence could not be performed due to three of the four
expected values being less than five. A Fisher Exact Test was therefore carried out.
This failed to reach significance (p>0.30) and supports the null hypothesis that
compliance and relapse are independent.
3.6.4. RELATIONSHIP BETWEEN RELAPSE AND SELF-EFFICACY
Pain management studies by Dolce et al. (1986a) and Kores et al. (1990) suggested
that self-efficacy expectancies could usefully predict maintenance with post-
treatment SE being a better predictor than pre-treatment SE. This hypothesis was
tested here by coding relapsers (1) and nonrelapsers (0) to obtain a maintenance
variable which was correlated with pre and post treatment SE scores (see Table
3.13). In line with the two papers mentioned above, the present study found SE
expectancies were associated with maintenance with post-treatment SE being more
strongly associated with maintenance than pre-treatment SE. Once again PSEQ was
found to be a more useful variable than DSE.
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Table 3.11: Pearson's product moment correlations between drug reduction and
Time 1-2 Self-Efficacy change
Drug Reduction
Change in Total PSEQ (n=28) 0.13
Change in Drug SE (Q7) (n=29) 0.17
Table 3.12: Compliance during group by maintenance during 1 month follow-up (n=19)
Table 3.13: Spearman's rho correlation coefficients between Self-Efficacy and








Total PSEQ Drug SE (Q7)
TIME 2
Total PSEQ Drug SE (Q7)
Maintenance 0.42* 0.13 0.68** 0.63**
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3.7. EIGHTEEN MONTH FOLLOW-UP
At 18 month follow-up data was collected on drug intake and SE from 23 of the 29
reducing subjects (a 79 per cent return rate). Two further subjects provided partial
information. In one case drug intake data had to be discarded as the participant had
just had a baby and had been warned against taking analgesic medication. On
telephoning the other, who had not responded by post, she said she could not be
bothered to provide the information and did not want to face up to the amount of
drugs she was consuming. However, she indicated that she was taking "a whole
mixture of different drugs that varied from day to day". This allowed her to be
classed as having relapsed between the end of the programme (when she had been
taking set drugs consistently as advised) and 18 months. No data was obtained from
four subjects. Three did not respond by post and could not be reached by telephone
and one replied that she was ill with another problem and had had to come off all
pain-related medication whilst tests were being carried out.
One of the 23 responders had started taking MST Continus (Morphine Sulphate)
over the 18 month follow-up period. This drug may be increased according to needs
and there is no maximum recommended daily dose. This meant it was not possible
to use the calculation devised (see Appendix E) to calculate whether this lady was a
relapser or non-relapser over the 18 month follow-up period. However, it was
decided to class her as a relapser as morphine is a strong opiate (prescribed as a last
resort) and its use is clearly a move in the opposite direction from drug reduction.
3.7.1. SELF-EFFICACY SCORES
In order to test the hypothesis that SE scores would show some relapse over the 18
month follow-up period, two repeated measures analyses of variance with one factor
(time) were performed on the data (see Table 3.14). As sphericity tests failed to
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Table 3.14: Repeated measures ANOVA of changes in Self-Efficacy over time
(n=29, except Time 4 n=24 and Time 2 PSEQ n=28)
Mean (Standard Deviaton)
Timel Time 2 Time 3 Time 4 F df
PSEQ Total 22.8 (8.3) 31.4 (12.2) 31.0 (13.5) 26.0 (12.6) 8.18 3,66***
Drug SE (Q7) 1.8 (1.1) 2.6 (1.9) 2.3 (2.1) 2.0 (2.0) 2.60 3,69
Table 3.15: Paired sample T-tests of changes in Self-Efficacy over time using the
Bonferroni method- 2 tailed sig.
MEAN SD MEAN SD t
Time 1 Time 2
PSEQ Total (n=28) 23.36 7.94 31.43 12.24 -4.47*
Drug SE(Q7) (n=29) 1.79 1.08 2.64 1.93 -2.31
Time 1 Time 3
PSEQ Total (n=29) 22.83 8.30 30.97 13.54 -4.15*
Drug SE(Q7) (n=29) 1.79 1.08 2.34 2.09 -1.66
Time 1 Time 4
PSEQ Total (n=24) 23.42 8.86 26.04 12.55 -1.34
Drug SE(Q7) (n=24) 1.92 1.10 2.04 1.99 -0.35
Time 2 Time 3
PSEQ Total (n=28) 31.43 12.24 31.64 13.28 -0.16
Drug SE(Q7) (n=29) 2.64 1.93 2.34 2.09 1.01
Time 2 Time 4
PSEQ Total (n=23) 32.17 13.18 26.61 12.52 2.64
Drug SE(Q7) (n=24) 2.77 2.00 2.04 1.99 1.87
Time 3 Time 4
PSEQ Total (n=24) 30.88 13.69 26.04 12.55 2.48
Drug SE(Q7) (n=24) 2.54 2.06 2.04 1.99 1.66
* significant beyond the 0.008 level set using the Bonferroni method
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indicate inequality of variance across repeated measures no modifications were
required.
(i) Pain Self-Efficacv Scores
On analysing the Total PSEQ scores a significant effect of Time was revealed ie. the
time when SE was measured affected the Total PSEQ scores obtained (F=8.183;
3,66df; p<0.00l). To find out where the differences lie paired sample t-tests using
the Bonferroni method were carried out (see Table 3.15). These showed SE scores
at Time 4 (26.0) to be similar to Time 1 (22.8) and Time 2 (31.4). However, there
was a significant difference between Time 1 and Time 2 (t = -4.47, df= 27, p<0.008,
2 tailed). Differences between Time 1 and Time 4 did not approach significance
(p=0.194) whereas comparison between Time 2 and Time 4 (p=0.015) was closer to
significance but failed to reach the requirement for the Bonferroni method involving
six comparisons of showing significance beyond the 0.008 level. Although the
differences were not significant, inspection of the means (see Table 3.14) indicates
that SE scores fell over thel 8 month follow-up period but Time 4 SE remained
slightly superior to Time 1 SE.
(ii) Drug Self-Efficacy Scores
There was no effect ofTime on analysing the DSE (Q7) data, ie. the time when SE
was measured did not affect the DSE scores obtained (F=2.598; 3,69df; ns).
Although there were no significant differences between the means, these illustrate
the predicted trend with a gradual return over follow-up to close to, but not reaching,
pre-treatment levels.
3.7.2. DRUG INTAKE SCORES
Relapse behaviour will be described as in 3.6.2 for the 19 participants who made a
reduction during the programme and for whom follow-up data is available.
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The 18 month drug intake data will be discussed more extensively than at one
month. Firstly, relapse is defined in terms of any increase in drug intake between the
end of treatment and 18 month follow-up. This led to 11 subjects being classed as
relapsers, five as reducers and one as a maintainer of partial reduction. The two
participants who had reduced to zero during the group were again maintainers of
abstinence.
Relapse is also investigated here by comparing 18 month follow-up with pre-
treatment levels. This produced four relapsers, 13 reducers and two maintainers who
were taking the same amount of medication at 18 months as at the start of the
programme.
Of the seven participants who did not make a reduction during the programme, four
returned information at 18 month follow-up. Three of these four were taking more
medication in comparison to pre-treatment levels and one was taking the same
amount ofmedication as at the start of the programme.
3.7.3. RELATIONSHIP BETWEEN RELAPSE AND NONADHERENCE
A further test of the hypothesis that those who were nonadherers during the group
would be more likely to relapse than the adherers was carried out. The subjects for
whom relapse was pertinent had been split into noncompliers and compliers in 3.6.3.
Compliers and noncomplicrs were then categorized as relapsers or non-relapsers by
comparing their drug intake at 18 months to their drug intake at (i) the end of the
programme and (ii) the start of the programme (see Table 3.16). As before, Chi-
squared Tests would be invalid and two Fisher Exact Tests were performed. Both
tests failed to reach significance: p>0.34 and p>0.16 with relapse being calculated
by method (i) and (ii) respectively. Therefore, as with the one month data,
compliance and relapse scores were found to be independent.
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Table 3.17: Spearman's rho correlation coefficients between Self-Efficacy and
maintenance - 1 tailed sig. (n=19)
TIME 1 TIME 2
Total PSEQ Drug SE (Q7) Total PSEQ Drug SE (Q7)
Maintenance:
Time 4 -2 0.22 0.45* 0.42* 0.41*
Maintenance:
Time 4 - 1 0.30 0.15 0.60** 0.68**
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3.7.4. RELATIONSHIP BETWEEN RELAPSE AND SELF-EFFICACY
The hypothesis that self-efficacy expectancies can usefully predict maintenance with
post-treatment SE being a better predictor than pre-treatment SE was tested further
using the 18 month follow-up data. Initially, a maintenance variable was calculated
using two methods: relapsers and nonrelapsers were coded with relapse being (i) any
increase in drug intake between post-treatment and 18 month follow-up and (ii) any
increase between pre-treatment and 18 months. The two maintenance variables were
then correlated with pre and post treatment SE scores (see Table 3.17). T his
supports, once again, the hypothesis that post-treatment SE is a useful predictor of
maintenance, with SE being more strongly correlated with maintenance when
calculated by method (ii) (r = 0.60, p<0.01, 1 tailed). PSEQ and DSE appear to be
equally useful measures post-treatment. However, the use of pre-treatment SE to
predict maintenance is no longer supported.
3.8. QUALITATIVE DATA
Participants tended to fall into four categories. Those who complied with their drug
reduction plans and reduced successfully over the course of the programme did so by
two methods: (i) systematic and gradual reduction (ii) sudden and complete
cessation. The majority reduced using method (i). Noncompliant participants either
(iii) reduced successfully (therefore by haphazard means) or (iv) failed to reduce. A
small number of participants were able to comply with their plans and reduce little
due to reduction plans being self-paced and flexible. This point is explained further
in 4.3.2.(B).
3.8. E ILLUSTRATIVE EXAMPLE - METHOD ti)
John was a 51 year old man who worked part-time in a legal office. He had suffered
neck pain for three years. At the start of the programme he was taking 50mg of
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Froben, 500mg ofCarbamazepine, lOOmg of Imipramine and two Co-proxamol (see
Appendix J) tablets daily. He was 100 per cent compliant with his plans which
involved weekly step-by-step reductions. Firstly, he stopped his Froben which he
believed was not helping his pain. He then reduced from two to one to zero Co-
proxamol tablets. Next he reduced his Carbamazepine by lOOmg a week. At the end
of the programme he had reduced to lOOmg of Carbamazepine and lOOmg of
Imipramine. At one month follow-up he was taking only 50mg of Imipramine.
Eighteen months later he had stopped his Imipramine but was taking, on average,
two Co-proxamol tablets every other day which he put down to increased working
hours.
3.8.2. ILLUSTRATIVE EXAMPLE - METHOD (ii)
Jean was a 36 year old social care nightshift worker who had suffered back pain for
17 years. Pre-treatment she was taking between four and eight Co-dydramol tablets
a day depending on whether she was working or not. She decided to stop taking her
drugs "cold turkey". During the first week of this plan she took two Co-dydramol
tablets on the four nights she was working and for the remaining six weeks of the
course she took no pain-related drugs. This produced a compliance score of 92 per
cent (ie. she was compliant with her plan on 92 per cent of days). At 1 and 18
months follow-up she remained medication-free.
3.8.3. ILLUSTRATIVE EXAMPLE - METHOD (iiil
Brian, a 49 year old man who was medically retired, had experienced back pain for
30 years. He made the largest reduction in his medication over the course of the
programme. He did so in a haphazard fashion, adhering to his reduction plan on only
42 per cent of'non-flare-up' days. Interestingly, he suffered a flare-up of his pain on
more days than any other participant, probably because he also adhered poorly to
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principles of pacing. Obtaining an estimate of Brian's initial intake was difficult as
he reported taking "handfuls" of pills. Detailed questioning produced an estimate of
1900mg ofZydol (for which the recommended maximum daily dose is 400mg) and
3500mg of Paracetamol daily. We suspected this man was also consuming some
alcohol. Post-treatment Brian had stopped his Paracetamol and was taking 600mg of
Zydol daily. At one month follow-up he had increased his intake by less than one
Zydol and one Paracetamol tablet a day. However, 18 months later he was off Zydol
and Paracetamol and had started on four new medications: 800mg Sulindac daily
(twice the recommended maximum daily dose), 180mg of Dihydrocodeine, 50mg of
Imipramine and 150mg of Voltarol daily! It would have been interesting to know
how much of this change had been instigated by his GP/Consultant and if they were
aware of his daily consumption. Unfortunately, Brian had to be excluded from the
analysis ofTPB data due to inadequate questionnaire completion (see 3.1.2).
3.8.4. ILLUSTRATIVE EXAMPLE - METHOD (iv)
Janet was a 42 year old housewife who had suffered rheumatic pain in multiple
joints for ten years. On an average day at the start of the programme she was taking
1500mg of Paracetamol, 90mg of Codeine and lOmg of Amitriptyline with much day
to day variation. She decided to reduce her Amitriptyline initially and cut down to
5mg for two days before returning to lOmgs. Early in the programme her
Paracetamol and Codeine were swapped for Co-proxamol by her GP. Although the
programme's Charge Nurse called this a "sideways move" in terms of amount of
analgesic, being on one rather than two tablets should have made establishing a
pattern easier. That was her next plan - to take a regular amount of Co-proxamol
each day. This was never achieved and she continued to take between zero and eight
tablets a day (with an average of six a day at the end of the programme). She was
judged to have adhered to her plan on 35 per cent of days. It should be noted that
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Janet travelled a round trip of 150 miles to attend the programme. Her average daily
intake at one month follow-up was lOmg ofAmitriptyline and 4.5 Co-proxamol
tablets and she had started on 4mg of Diazepam daily. Eighteen months later her
Amitriptyline was unchanged and her Co-proxamol had been switched for Co-
codamol of which she was taking five a day (still variable). Diazepam had been
discontinued. Thus she had no greater success in applying the principles of drug
reduction when travelling was no longer an issue.
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4. DISCUSSION
4.1. COMMENTS AND CRITICISMS OF METHODOLOGY
4.1.1. SAMPLE
It is important to note how far the present sample was representative of chronic pain
management patients who take drugs for their pain. The INPUT programme, used
for comparison purposes, is the largest UK programme to collect background
measures which are similar to the AAH. It should be noted that this is an inpatient
programme although selection criteria are similar to the AAH programme. It should
also be noted that the INPUT population includes all patients who completed
treatment regardless ofmedication use. The age, duration of pain and depression
and self-efficacy scores of the current sample appear to be reasonably representative
of chronic pain management patients but the sex ratio is less so. It is possible that
the present sample is more representative of pain management patients who use
medication. However generalisation from the present sample requires caution as this
small sample may include more females and it is not possible to conclude how
representative it is in terms of self-reported dysfunction. Comparison of participants
opting in and out of drug reduction in the current study would have been useful but
was not carried out due to the small number opting out.
4.1.2. TPB Ol JESTIONNAIRE: HOW VALID IS THIS NHWI ,Y DEVISED
MEASURE?
Reliability analysis provided weak support for the belief-based measure of attitude
and the perceived barriers scores. However reliability analysis was not conducted on
the other variable totals due to them being comprised of three items or less. The
inter-variable correlations provided some support for the questionnaire. The direct
measure of PBC seems to be of little predictive value and had no significant
67
associations with other measures in the model. The perceived control part of the
score was measured by two items of which one did not adequately differentiate the
participants. The SE part of the score was measured using Q7 of the PSEQ. This
assessed confidence in ability to cope without medication rather than ability to
reduce medication. Using an item such as "For me to reduce my drugs will be easy -
difficult" would have been more in line with previous studies. Unfortunately it was
not possible to extensively validate the questionnaire due to lack of time and
availability of existing materials. Test-retest reliability analyses were not carried
out. Whilst these results provide some initial optimism, much caution is required in
interpreting results. Handling of the PBC variable, in particular, requires care.
Future research would be strengthened if this measure included more items.
Ajzen (1991) suggested that assessment of perceived barriers should cover the
presence or absence of resources and opportunities, together with obstacles and
impediments to performance of the behaviour and be weighted by their perceived
power to facilitate or inhibit performance. Many of the research papers referred to
by the author when the questionnaire was being designed (eg. Norman & Smith,
1995; Winkelstein & Feldman, 1993) assessed perceived barriers using only one of
these two steps. The present subjects were provided with a set of perceived barriers
(eg. sleeping badly) which they interpreted in one of two ways: "If 1 am sleeping
badly would that prevent me reducing my drugs?" or "Do 1 or do I not sleep badly?"
Hopefully, despite this inconsistency, both interpretations provide useful information
about the extent the factor is perceived to be a barrier.
There were some general ways in which the questionnaire and its administration
could be improved. A few questions used long words (eg. "outweigh" in Q9) or
double negatives (Q7) and would benefit from simplification. The wording used in
one or two of the items could be tightened, eg. the addition of "unwanted" side-
effects to Q10 would be helpful. It was necessary when devising the questionnaire to
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achieve a balance between item inclusiveness and length so as not to overburden the
subjects. Nevertheless, concentration problems, as a result of pain, medication or
fatigue, may have affected questionnaire responses. Due to a lack of free time
during the groups patients were sometimes completing the questionnaires in haste.
Thus, allowing completion at home may have been the preferable option although
this had been decided against initially due to anticipated problems of non-return.
4.1.3. MEASUREMENT OF ADHERENCE: HOW VALID ARE THE METHODS
EMPLOYED?
Measurement of compliance turned out to be a complex process. Comments on the
strategies employed are contained in Appendix E. Unfortunately the use of other
non-prescribed substances (eg. alcohol, cannabis) to control pain was not measured.
However, the one participant who was known to abuse alcohol was omitted from the
main analysis due to inadequate questionnaire completion.
Given the points raised in the introduction, the compliance scores are surprisingly
high suggesting that the drug reduction plans were realistic and appropriate.
Compliance may be increased as a result of the self-monitoring procedure. In
contrast drug reduction scores were generally quite low with some subjects failing to
reduce and even increasing their medication intake. There were three subjects who
came off their drugs completely during the programme. They all chose to stop "cold
turkey" as opposed to gradual reduction.
Measurement of compliance can be criticised for relying solely on self-report which
may be biased by such factors as memory and social desirability, as discussed earlier.
Again adherence figures from existing studies are not available to assist validation.
Overall reports of compliance are quite high in the present study, compared to other
demanding regimes, possibly providing grounds for suspicion.
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Nevertheless, there are reasons to have confidence in the self-report data. Firstly, as
the main purpose of recording was for use in negotiation of drug reduction plans,
dishonesty would result in future plans being meaningless and even less achievable.
Furthermore, weekly discussions with the nurse about the plans allowed for
verification. A "no fault approach" was taken with it being acknowledged that
participants might take more than the agreed dosage at times. There was no
evidence of subjects having difficulty understanding the recording form or attending
with their weekly records incomplete. Self-report was likely to be less accurate with
the one or two subjects on a large number of pills. For example, the participant on
seven prescribed medications found the recording sheet too small and a larger format
would be useful for such subjects in the future. Also, recording of intake initially
and at follow-up may be more questionable when verification was not possible.
Finally, it was a concern initially that participants would report being in flare-up for
much of the time. However, as no participant claimed to be in flare-up for more than
40 per cent of the time, it was assumed that participants were being appropriate in
their flare-up reporting.
The moderate correlation (obtained on removing the atypical subject) between the
measures of drug reduction and compliance was expected. It was possible for
subjects to comply and reduce little as the speed of reduction was self-paced and
flexible. It was also feasible for participants to reduce effectively whilst paying little
attention to their plans (see 3.6.5.- Brian). Thus inferring compliance from clinical
outcome, as is generally done in pain management studies, may be a fairly inaccurate
procedure.
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4.2. COMPARISON OF SUBJECTS OPTING IN AND OIJT OF DRUG
REDUCTION
The small numbers who opted out of drug reduction prevent any firm conclusions
being drawn. It is disappointing that the ability of the TPB to predict opting in and
out of drug reduction could not have been examined using regression analysis, as
looking at the means of these two groups show that all differences are in the
expected direction, ie. those opting in expressed more favourable attitudes towards
drug reduction. It was expected that this group would be very much against
reduction given that they opted out despite a strong recommendation to reduce.
The subjective norm difference is especially marked suggesting that those opting out
of drug reduction might be particularly encouraged to do so by perceiving drug
reduction to be against the wishes of their families and doctors. Unfortunately
attendance at the family sessions tends to be low and therefore changing the views of
family members is likely to be difficult. Surprisingly, intention to reduce is
reasonably high in the group opting out who shortly after completing the
questionnaire refused to participate in a drug reduction plan. However, as the
question measuring intention did not specify a time span it is possible that these
people did hope to reduce eventually without intending to do so immediately.
Unexpectedly, two or three members of this group did go on to reduce a small
amount of medication without reporting this to the group until discharge. Therefore
they may have intended to reduce but, possibly due to an expectation of failure or a
fear of pressure, wanted to work independently.
Conclusions regarding the increase in perceived barriers and self-efficacy variables
over the course of the group in the subjects opting out are confounded by the two or
three patients who went on to reduce independently. If this had not occurred the 'opt
out' group could have served as a 'control group' who had attended the programme
but had no experience of reducing their drugs.
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4.3. ACCOUNTING FOR THE VARIANCE IN ADHERENCE AND DRUG
REDUCTION
4.3.1. DEMOGRAPHIC AND BACKGROUND VARIABLES
The lack of a moderate correlation between the demographic variables and
compliance/drug reduction is consistent with the literature but a stronger association
with number of drugs was expected. This correlation may be weaker than
anticipated since subjects were advised to target one drug at a time whilst keeping
the rest of their medication stable. A moderate association was observed between
perception of support received for drug reduction and amount of drugs reduced.
There are at least two explanations for this correlation. Firstly, some patients
received more attention and not surprisingly their reduction scores were higher. This
seems unlikely since, if anything, those reducing well tended to receive less
attention. Perhaps, more likely, people's perception of support relates to their
satisfaction with the drug reduction component of the course. This is likely to be
higher if the subject reduced successfully. If so the correlation would represent an
effect and not a cause of drug reduction.
4.3.2. TPB VARIABLES
(A) Accounting for the Variance in Intention
Partial support was obtained for this part of the model with the measures of attitude
and subjective norm making significant contributions to the prediction of intention
(see Fig. 3.2, page 50). Therefore, as expected, favourable attitudes to reduction and
approval of reduction from significant others relate to positive intentions to reduce.
The amount of perceived control over drug reduction and the number of perceived
barriers was not found to influence intention to reduce. Therefore, in effect support
has been obtained for the Theory ofReasoned Action and not the TPB. The lack of
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support for PBC could be due to inadequate measurement in the current study (see
4.1.2) and is discussed in more detail in 3.2.3.
(B) Accounting for the Variance in Adherence
No support was obtained for the model in this case, with these variables failing to
predict adherence. One explanation for this failure is that the newly designed
questionnaire measured attitudes towards drug reduction and not attitudes towards
adherence with drug reduction plans. The reason for this was to facilitate ease of
completion. Obviously it is simpler for people to rate, for example, "If I reduce my
drugs my self-confidence will improve" compared to "If I stick to my drug reduction
plans, my self-confidence will improve". It is very unlikely that entirely different
sets of attitudes would predict drug reduction and adherence but possible for people
to intend to reduce without intending to go about it in the style recommended by the
programme. There appeared to be a few subjects who felt that aspects of the method
of reduction (eg. time-controlled intake, reducing one drug at a time) were not
appropriate for them.
However a stronger reason for the theory's lack of success may be that the patient-
controlled nature of drug reduction has become confounded with adherence. Since
patients held an element of control over how quickly they worked through their
plans, it was possible for subjects (perhaps with less positive attitudes about drug
reduction) to move through their plans more slowly whilst remaining compliant. In
fact it may even have been easier for these patients to be compliant if their reduction
plans were less demanding and involved fewer changes. A few subjects were noted
to have high compliance scores whilst reducing little. Thus the TPB should be better
able to explain the speed of progress through plans or actual drug reduction as
opposed to compliance.
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(C) Accounting for the Variance in Drug Reduction
Unusual results were obtained here, with the measure of attitude making a
significant positive contribution to the prediction of drug reduction and the measure
of intention making a significant negative contribution to this prediction (see Fig.
3.3, page 50). Therefore, as expected, favourable attitudes to reduction and,
surprisingly, negative intent to reduce relate to greater drug reduction. Subjective
norms and perceived control were not found to influence drug reduction.
Firstly, to explore the unusual result of negative intention, drug reduction and
intention were plotted as in Appendix K. This failed to show a direct negative
relationship between the two variables but obviously does not shed light on what
happens to intention when the other TPL3 variables are present. Suppressor variables
are sometimes discussed when attempting to explain seemingly unreasonable
variables. It may be that intention is acting here as a suppressor variable which
enhances the importance of other variables by suppressing irrelevant variance in
other independent variables or the dependent variable.
It should be noted that the measure of intention was based on one item (I am going to
reduce my drugs) which despite providing a good overall range of responses (two to
seven), the vast majority (26 of the 28) fell between four and seven. The majority of
studies referred to used two or three items to assess intention and use of, for
example, "1 intend to reduce my drugs" and/or "I will try to reduce my drugs" at
different points in the questionnaire may have been preferable.
Another possibility for the lack of a positive association between drug reduction and
intention is that general traits such as confidence and optimism were inlluencing
how people responded to the intention question. There was a feeling that those who
had low intent but went on to reduce were cautious about their chance of success.
They may have scored more highly if the intention question had been rephrased as "I
am going to try to reduce my drugs". In contrast, those who had a high intent but
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reduced little may have had a rather unrealistic, overconfident approach, believing
that reduction would be easy. In fact, these styles may have reflected whether people
approached reduction methodically or haphazardly possibly influencing their success
on reduction. However, if this is the case, it is not clear why these traits have
contributed to this behaviour but not to others studied.
A further reason to explain why people with strong intentions to reduce may not have
done so is that the item did not specify a time span. The item may have been more
useful in predicting drug reduction if it had included a time frame, ie. "1 am going to
reduce my drugs during the programme". Many chronic pain patients may believe
that one day their pain or their management of it will improve and therefore they
may have a positive long term intention to reduce with little immediate motivation.
Bagozzi & Kimmel (1995) observed that a gap in time exists between the decision to
act and the opportunity for action. Time gaps were present in this study between
completing the questionnaire and meeting the nurse to specify a plan and actually
carrying out a reduction step. In some cases this process was quite lengthy if patients
initially worked towards time-controlled intake. Thus once activated the intention is
likely to undergo further processing and elaboration, eg. planning, monitoring.
Therefore models that deal with process and appraisal, eg. The Self Regulation
Model (Leventhal & Nerenz,1985), Transtheoretical Model ofChange (Prochaska &
DiClemente, 1982) may be better able to explain the negative effect of intention.
A lack of support was obtained for subjective norms which is in keeping with much
of the literature. Subjective norms failed to significantly predict behaviours in 10 of
19 investigations summarized by Ajzen (1991). Ajzen (1988) is able to deal with
these inconsistent results by stating that the contribution of attitudes and subjective
norms will vary from situation to situation. Terry & O'Leary (1995) suggest that
even though people may perceive that others would wish them to reduce in this case,
the fact that failing to do so is unlikely to have immediate detrimental effects may
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mean that they are not particularly motivated to comply with this social pressure.
Informal comments made by some patients in the present study indicated that they
felt quite strongly that the views of others were not important to them, eg. "it's not up
to them, it's up to me", "they don't know how much I take". Possibly because of the
nature of suffering pain and the strong desire for relief, the approval or disapproval
of others is less important here than with some behaviours. Furthermore, drug intake
may be one area where the patients feel they can retain some independence.
Perception of fewer barriers to drug reduction was related to greater drug reduction
prior to the entry of attitudes and subjective norms into the analysis. However, when
these variables were entered, they (effectively attitudes) explained all of the variance
that the perceived barriers variable had been explaining. On devising the
questionnaire I had been aware that many concepts could have been expressed as a
barrier (eg. Not being able to do as much) and/or a belief-based attitude (eg. If I
reduce my drugs, I will not be able to do as much). This may illustrate poor
interpretation of the theory on my part but provides an explanation for the shared
variance. It is not possible to comment on whether a causal relationship exists
between perceived barriers and attitudes.
The lack of support for the PBC measures is difficult to interpret as the method of
measuring PBC may have been poor in the present study. This result is in keeping
with the Theory ofReasoned Action and not the TPB. The former was intended for
application of behaviours under voluntary control but drug reduction is a domain in
which voluntary control was anticipated to be incomplete. Even if its execution is
not dependent on other people, it is conceivable that the person will lack the
alternative coping skills required to perform the behaviour.
The PBC - behaviour link in the model is hypothesized to represent actual control.
De Vries, Dijkstra & Kuhlman (1988) argued that the correspondence between
actual and perceived control could be low if individuals are not familiar with the task
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or when behaviour is complex and dependent on several variables. Many of the
subjects may not have tried to reduce in the past, and the second explanation referred
to may also be true, given the importance of developing alternative coping strategies
and the presumed contribution of pharmacological and biological factors.
Finally, Terry & O'Leary (1995) criticized Ajzen for confounding variables by
combining the notions of perceived control and self-efficacy into the concept of
perceived behavioural control. They found evidence for incorporating the concepts
of perceived behavioural control and sel f-efficacy as two separate variables in the
model and reported that the effects of the two components on intentions and actual
behaviour differed. These interesting results require replication. Previous evidence
in support of a PBC effect may have been due to previous measures primarily
assessing efficacy expectancies (Terry & O'Leary, 1995). Therefore SE alone may
have been influential here but was being masked by the use of a combined variable.
A final possible reason for the overall weak and variable support for the TPB is that
other variables, not included in the theory, may be of greater importance in
accounting for compliance and drug reduction. Some feelings were gleaned from the
subjects about which other cognitive and noncognitive variables might be influential.
In keeping with Leventhal & Nerenz's (1985) Self-Regulation Model, there was some
suggestion that patients' own "common sense" notions about their pain and
medication were interfering with drug reduction planning and compliance. For
example, two or three subjects resisted taking their medication on a time-controlled
basis believing that to do so would not suit their particular condition. Effects of
prior experience, which Bagozzi & Kimmel (1995) claim contribute over and above
the TPB, seem likely to be important. Subjects' comments indicated that these
experiences served as reference points for them, sometimes influencing the way
plans were drawn up. For instance, one patient wanted to reduce two drugs in
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tandem which she knew from past experience only worked if taken together. Prior
experiences appear to have been variable with some patients having reduced
successfully on their own and others encountering difficulties such as withdrawal
symptoms.
Other noncognitive variables could also be important. On looking at some of the
reasons provided for nonadherence, Ley's (1982) comprehension and memory
variables were mentioned. Occasionally a subject admitted to forgetting to follow a
medication instruction. Failures in communication were observed between staff and
patients in both directions. Once or twice, due to time pressures on staff, plans were
not specified as clearly as possible. On speaking to a patient's spouse it transpired
that the patient had reasons for believing that the plan he negotiated was not
appropriate for him but he failed to articulate this effectively to the nurse. Finally
some miscellaneous reasons were provided for nonadherence. These included taking
less tablets to compensate for taking additional medication for another ailment or
because a couple of glasses of wine had been consumed.
4.3.3. SELF-EFFICACY VARIABLES
Scores on the PSEQ suggest drug reduction is an area where people are particularly
lacking in confidence and this is not strongly related to their full PSEQ score. These
findings are consistent with Nicholas' (1994) validation report on the PSEQ.
Terry & O'Leary's (1995) adaptation of the TPB predicts separate effects of PBC and
SE with SE having an effect on intention with no direct effect on behaviour. Some
support was obtained for this model. The correlation of 0.30 between Drug Self-
efficacy (DSE) and intention is higher than that of 0.19 between PBC and intention
suggesting that SE could be more influential on intention but is being masked by
PBC. Furthermore, DSE was weakly associated with intention but not behaviour.
However, the correlations involving DSE were weak and, like PBC, may not have
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been significant if tested as part of the model with the present sample. Research
involving a larger number of subjects would allow testing of Terry & O'Leary's
model.
The significant contribution of PSEQ to compliance and drug reduction provides
some support for the Self-Efficacy Theory and is in line with pain management
studies which suggest that self-efficacy expectancies may be useful predictors of
treatment outcome (Dolce et al., 1986a, Kores et al., 1990). It is interesting that this
general pain measure has one of the highest simple correlations with drug reduction
obtained in this study. This is likely to be because high PSEQ scores should reflect
greater confidence in developing the alternative coping strategies required if drug
reduction is to be successful. This also explains why DSE is a better predictor of
intention (which does not require action) but behaviour, which is hypothesized to
require skills in addition to intention, is better predicted by PSEQ.
4.3.4. DECISIONAL BALANCE VARIABLE
The lack of association between the decisional balance type question and
compliance/drug reduction is perhaps not surprising since it asks nothing about the
person's confidence or ability to reduce. Furthermore, little detailed information is
obtained as patients score zero or one and we do not gain information on whether the
decision was a difficult or clear-cut one. Finally, several people were observed to
have difficulty understanding the rather wordy question.
4.4. CHANGE DURING PROGRAMME
4.4.1. TPR VARIABLES
Interpretation of change in TPB variables is especially difficult given the lack of test-
retest reliability data for the new questionnaire. The following discussion is
therefore preliminary.
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Disappointingly, the experience of attending the programme and working on a drug
reduction plan failed to bring about a change in attitudes. This may reflect the rather
small amounts of drugs reduced, if at all, resulting in few experiences of success. It
is possible that the attitudes of people who succeeded in reducing have become more
positive towards drug reduction whilst the attitudes of those who have experienced
failure have become more negative. If so, the two changes could have cancelled
each other out. However, if this were the case one would expect to see an increase in
the range of scores obtained but this was not apparent.
A more likely explanation is that expectations of change may have been somewhat
unrealistic given the limited time spent on directly challenging attitudes during the
programme. The lack of change could, in fact, be viewed as providing support for
the model. As the model predicts that people with positive attitudes will succeed in
drug reduction and vice versa, then those experiencing success should be the ones
whose attitudes were initially favourable.
Initial perception of barriers was found to be significantly higher than reports of
actual occurrence of barriers at discharge. Individualized item analysis demonstrated
that this difference was present for eight items and that four items had been
perceived accurately, with the initial anticipated barriers being rated similarly to the
actual occurring barriers.
The eight items could represent an inaccurate initial perception of how likely
potential barriers are in preventing drug reduction or they could have been
anticipated correctly but attending the programme Avorking on a drug reduction plan
altered how much these items prevented reduction. This possibility is supported by
looking at which barriers were scored differently at Time 2. The eight items were all
things which the programme would hope to influence with the possible exception of
suffering a new pain or injury (which is quite likely not to have occurred over the
short time span of the group.) In contrast three of the four non-changing items are
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barriers which the programme has little control over, ie. family pressure, other
medical professions and withdrawal symptoms. However improvement on the
barrier "sleeping badly" would have been hoped for.
Further examination of the mean scores illustrates that suffering a pain flare-up and
sleeping badly were rated as the most likely to have prevented drug reduction. It
seems the group may be of some use in reducing flare-ups but is not improving sleep
difficulties. Being pressurized by families was rated as one of the least likely factors
to have prevented drug reduction which is fortunate given the difficulties
encountered in trying to alter the behaviour of families.
It may have been more interesting to have readministered the same question to assess
whether there had been a change in the perception of barriers. Given the results of
the regression analyses it may be less important to try to change perceived barriers
than attitudes. However, given the strong simple correlation between perceived
barriers and drug reduction and the possible influence of barriers on attitudes, it
seems worthwhile to try to effect a change and encouraging that one has occurred.
4.4.2. SELF-EFFICACY VARIABLES
As hypothesized there were significant increases in DSE and PSEQ over the course
of the group and working on a drug reduction plan. This will be of interest to the
AAH PMP staff when considering how best to demonstrate group effectiveness to
their funders. These results are consistent with other studies (eg. Dolce et al., 1986a;
Kores et al., 1990) which reported significant increases in self-efficacy following
pain management input. However, the increases are not as impressive as those
achieved by the INPUT sample (Williams et al., 1993). They report a change in
mean PSEQ score of 16.6 over the course of their inpatient programme compared to
a mean increase of 8.4 at the AAH PMP. Change on the DSE item was relatively
small with the mean score failing to reach the midpoint of three (meaning neither
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confident or unconfident about coping with pain without medication). This may be
suggestive of a rather weak intervention.
Change in PSEQ was not found to correlate with drug reduction suggesting that the
increases in self-efficacy had more to do with such factors as receiving general pain
management input, success or failure on other course regimens and nonspecific
treatment effects than success or failure on drug reduction. It was more surprising
that change in DSE was not more closely related to drug reduction. However, this
too may reflect the increase in alternative coping strategies (eg. relaxation, pacing)
available following group attendance.
4.4.3. DRUG INTAKE SCORES
Studies of pain management programmes have used different criteria for success
making comparison of results difficult. Medication behaviour is frequently
described in terms of "numbers remaining medication free". To use this stringent
description here would indicate little success. In contrast, the more liberal criterion
(eg. any reduction) shows that around three-quarters of participants made a positive,
albeit small, change. The extent of this change is less favourable than in many of the
published studies. For example, Dolce et al. (1986a) reported 97 per cent of their
subjects becoming medication free over the course of the programme compared to
just ten per cent in this study. Some of this variation may reflect differences between
inpatient and outpatient treatment and Patient-Controlled Reduction and Staff-
Controlled Reduction. Also, the mean duration of pain, and therefore likely duration
of drug use, in this study is longer than in many other studies. The mean duration of
pain in the Dolce study was 3.2 years compared to 12.5 years in the present study.
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4.5. MAINTENANCE OF CHANGE: ONE MONTH FOLLOW-UP
It is necessary to first of all define "relapse" before discussing it more fully in this
section of the study. Strictly, relapse could be considered to be any increase in drug
use (after planning a period of reduction) or, more conventionally, it could be
defined as a return (in the follow-up period) to pre-treatment levels of morbidity
(Saunders & Allsop, 1987). Both definitions have weaknesses according to Saunders
& Allsop. The former fails to acknowledge any notion of gradation in the severity or
duration of the relapse and the latter involves the end point of a process and does not
consider those moving towards that point. Turk & Rudy (1991), therefore, advise
comparing post-treatment with follow-up with the pre-treatment data as an anchor.
The one month data will be analysed here using the former approach, ie. relapse
being any increase in drug intake between the end of treatment and one month
follow-up. However, the more useful 18 month data will be analysed more
extensively following Turk & Rudy's (1991) advice. Firstly, relapse will be
discussed in terms of any increase in drug intake between the end of treatment and
18 month follow-up. It will then be investigated by comparing 18 month follow-up
with pre-treatment levels.
Follow-up studies require to be interpreted with caution as they are based on only the
percentage of the sample who are available and willing to participate in follow-up
assessment. Results can vary depending on how studies deal with those who do not
respond. Turk & Rudy (1991) differentiate between a "best case" strategy (where
relapse rates are completed using available cases only with those not available being
discarded) and the more cautious "worst case" strategy (were all nonresponders are
counted as failures). They argue that the "truth" is likely to lie somewhere in
between the conclusions based on these two approaches. The "best case" strategy
appears to be the most commonly used method in evaluating pain management
programmes and was employed in this study. This allows comparison with other
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pain management studies but may underestimate the extent of relapse, as those who
did not comply with follow-up requests may be more likely to have been
noncompliant with treatment and fallen into the relapse category. However, this is a
minimal problem here as relapse rates were obtained from a 100 per cent return rate
at 1 month and from 79 per cent of subjects at 18 months. This compares very
favourably with other chronic pain treatment follow-up studies in which the
percentage of patients included ranged from 12-70 per cent (Turk & Rudy, 1991).
This is likely to be due to the present researcher pursuing the participants, with
whom she was acquainted, by telephone. Furthermore, three of the six excluded
subjects at 18 months did respond to the follow-up request but their case was ignored
because of inaccurate record completion or life events (eg. illness, giving birth)
resulting in atypical abstinence from drugs. Two of the remaining three had adhered
poorly to their drug reduction plans during the programme.
Nicholas (1992) highlights the danger that follow-up results in a given patient may
simply reflect the natural fluctuations in this chronic condition rather than the effects
of treatment. As is often the case in follow-up studies, individuals were targeted at
fixed points in time (ie. 1 month and 18 months) and it is not possible to judge the
representativeness of these weeks for each individual. It is hoped, however, that
those experiencing atypically good or bad weeks (in terms of drugs consumed)
would even out across the sample. Interviewing would allow more detailed process
information to be gathered such as whether a relapser had increased his or her drugs
steadily or attempted further reduction but encountered problems. Finally, as with
earlier stages of the study, the follow-up assessment relies on self-report and is
therefore subject to the concerns discussed in 1.3.2. and 4.1.3. Self-report may be
more questionable at follow-up when the participants are no longer attending the
PMP, which had allowed for some verification of self-report through discussion with
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the nurse. Alternatively, it could be argued that this would reduce pressure for social
desirability and facilitate honesty.
4.5.1. SELF-EFFICACY SCORES
No changes were observed in drug or pain self-efficacy between subjects being
discharged from the group and one month follow-up. These results are consistent
with other pain management studies (eg. Williams et al. (1993) noted improvements
in mean SE scores were maintained at one and six months) and will also provide
reassurance to the pain management team. However, a follow-up period of one
month is extremely short and the results at 18 months are of greater interest.
4.5.2. DRUG INTAKE SCORES
Of the 76 per cent who progressed with drug reduction during the group, the largest
subgroup (seven of the 19 - 37 per cent) did not change their level of drug intake
over the follow-up period having made a partial reduction on the programme. One
of this group had to deal with travelling and family stress in the month following the
group.
A disturbing number (six of the 19-31.5 per cent) had relapsed to some extent
(although one had managed to maintain much of a large reduction). This is in
keeping with other pain management studies. For example, Dolce et al. (1986a)
noted a relapse figure, in terms of numbers remaining medication free, of almost one
third at 6 and 12 month follow-up. The fact that a similar relapse rate was obtained
in this study after only one month could be viewed more negatively, ie. further
relapse might be predicted. However, Williams et al. (1993) reported an initial
relapse in opioid analgesics at one month but no further decrease at six months.
A subgroup of four subjects (21 per cent) reduced their intake over the month. This
included people who had been reducing systematically during the course and had
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been able to continue to implement a reduction plan by themselves and people who
had reduced in a rather haphazard and independent fashion on the course and
continued to do so successfully. The two participants (10.5 per cent) who had
reduced their drugs entirely whilst on the programme both maintained this gain.
Of interest, one participant who failed to make a reduction during the programme
made a significant reduction during the one month follow-up period. The physical
demands on this person had eased during the follow-up month as she no longer had
to travel a long distance to attend the course and had given up her job.
4.5.3. RELATIONSHIP BETWEEN RELAPSE AND NONCOMPLIANCE
The results of the Fisher Exact Test suggest that noncompliers are no more likely to
relapse than compilers. However, the number of non-compliers was small after
those who had not made a reduction were removed. Interestingly, five of the seven
participants who did not reduce their drugs were noncompliers. This fact and the
moderate correlation reported in 3.2.3 suggests that compliance with plans is more
closely related to drug reduction during the group than later relapse. In those that do
make a reduction, complying with the PCR method of reduction which is
implemented at the AAH PMP may not be any more effective in preventing relapse
than haphazard reduction. Only preliminary conclusions can be drawn at this stage
due to the shortness of the follow-up period and this area will be discussed in more
detail with the 18 month data.
4.5.4. RELATIONSHIP BETWEEN RELAPSE AND SELF-EFFICACY
In keeping with previous pain management studies (eg. Dolce et al., 1986a; Kores et
al., 1990) post treatment SE was found to be associated with maintenance in the
current study.
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Dolce et al. (1986b) had suggested that a subgroup of chronic pain patients exist who
fail to display improvements in SE despite experiencing success and who are good
candidates for relapse. In the current sample, of the five subjects who did not show
SE increases despite experiencing some success, three relapsed. Little can be
concluded from these small numbers and experiences of success or failure on the
other programme regimens requires to be taken into account. However, this trend
does not contradict Dolce et al.'s hypothesis.
4.6. EIGHTEEN MONTH FOLLOW-UP
4.6.1. SELF-EFFICACY SCORES
No change (ie. no relapse or further improvement) was observed in PSEQ scores
over the 18 month follow-up period. However, an anomaly exists in the statistics
that reduces optimism. Although PSEQ scores increased significantly between Time
1 and 2 and did not relapse thereafter, there is no difference in the PSEQ scores at
pre-treatment and 18 month follow-up. Analysis of the drug SE scores now indicates
no change over time. Thus there was no increase during the programme and no
change in follow-up. This result goes against the finding of 3.5.2. where drug SE
was shown to have increased during the programme.
Williams (1998) raised the distinction between statistical and clinical significance
and highlighted the need to think of alternative ways of analysing data. The raw data
is of interest clinically to the staff at the AALI. These show, despite lack of
significance, some relapse in drug and pain SE between subjects being discharged
from the group and 18 months later, in keeping with the relapse literature (see 1.1).
Therefore, the optimism held at one month follow-up should not be maintained
following a lengthier time interval. However, on comparing the SE scores at 18
months with pre-treatment SE, overall progress, albeit not statistically significant,
has been made. Given the therapeutic importance of self-efficacy, this small
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improvement may be of clinical significance in improving outcome. The concern is
whether this improvement will continue to be eroded with time.
4.6.2. DRUG INTAKE SCORES
On initially investigating relapse by comparing drugs taken at 18 month follow-up
with the end of the programme the data is not encouraging. The majority, 11 of the
19 subjects (58 per cent) had increased their drug intake over the 18 months. These
results are typical of the chronic pain relapse literature (see 1.1). Keefe et al. (1986)
suggested between 30 per cent and 70 per cent of patients attending chronic pain
treatment programmes relapse over a one year to five year period. In the current
study more people were found to have relapsed by this definition at 18 months (58
per cent) compared to one month (31.5 per cent). This increase in relapse over time
supports the findings of Cinciripini and Floreen (1982), who found numbers
remaining free of medication increased between 6 and 12 months, but is
contradictory to the more optimistic results ofWilliams et al. (1993). They reported
an initial relapse in opioid analgesics at one month but no further decrease at six
months. Extrapolating from the current results would suggest further relapse over a
longer time period.
One of the 19 subjects (5 per cent) was taking the same amount of drugs at 18
months as at the end of the programme with five of the 19 subjects (26 per cent)
actually reducing their medication over the 18 months. Few of the patients had
stopped taking medication completely during the programme (unlike in many of the
comparison studies) but one quarter, as hoped, used the skills they had learnt on the
programme to continue with their reductions. Impressively, the two achievers of
abstinence during the programme (11 per cent) had maintained this abstinence at 18
months.
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There is an expectation, from writing on relapse and chronic pain, that people will
relapse to a certain extent following treatment. The key question is therefore
whether this relapse is back to pre-treatment levels making redundant the time and
cost expended. On comparing intake at 18 months with pre-treatment levels the data
is more encouraging. Now only four of the 19 subjects (ie. 21 per cent) are
categorized as relapsers. These four were taking more drugs at 18 month follow-up
compared to pre-treatment.
Two of the 19 subjects (10.5 per cent ) were taking the same quantity of drugs 1 8
months after treatment compared to pre-treatment. It would have been interesting to
have compared these results with the chronic pain patients who did not chose to
work on drug reduction plans. If there is a tendency to gradually increase drug
intake over time, it may be that these two subjects would have increased their drug
use without the input they received on drug reduction. This argument could even be
extended to those who relapsed - the extent of relapse may be less as a result of
attempted work on drug reduction. A study involving a control group is required to
shed light on these speculations.
A healthier 13 out of 19 subjects (68.5 per cent) were taking less medication at 1 8
months compared to pre-treatment. Overall these patients appear to have benefited
from the programme although it may be that some or all of them will relapse back to
pre-treatmcnt levels over a longer period. However, it could be argued that even if
they do revert back to pre-treatment levels they will still have benefited from taking
less toxic medication for a period of time although this work may not have been
cost-effective to the NHS. In addition, they will possess the skills which may enable
them to re-attempt reduction at a later date.
It might have been hoped that those who did not progress during the programme
would find the period after treatment more conducive to reduction, eg. when the
pressures of attending the hospital had been removed. The follow-up return rate at
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18 months in this group (four out of seven - 57 per cent) was poorer than in the full
sample (79 per cent). None of the four cases had success in maintaining a reduction
post-treatment.
In summary, seven of the full sample of 29 (24 per cent) demonstrated a problem
getting started with drug reduction. A further 11 (38 per cent) showed some problem
with relapse (in five (17 per cent) relapse was partial and in six cases (21%) all of
the treatment gain was eroded). Eight of the 29 (28%) made progress and did not
relapse afterwards. Finally, three of the 29 (10%) made a reduction but were
excluded from 1 8 month follow-up due to special factors or non-return (see 3.7).
4.6.3. RELATIONSHIP BETWEEN RELAPSE AND NONCOMPLIANCE
Regardless of the method for calculating relapse, the 18 month results are consistent
with the conclusions drawn at one month, ie. noncompliers during the group are no
more likely to relapse than compilers. These conclusions are now less tentative due
to the reasonable length of follow-up period, however, numbers remain small,
especially of those failing to comply. Also, if compilers and noncompliers were
categorized by a different strategy, perhaps resulting in a greater number of
noncompliers who had made a reduction, different conclusions may be reached.
However, there is not another natural division in the compliance scores and it seems
just as likely that relapse is related to a different set of factors than compliance.
Therefore, compliance with the drug reduction plans advocated at the AAHPMP
appears to be important in whether participants end up making or not making a
reduction in their drugs after planning to do so. Relapse in drug intake, however,
seems to be influenced by additional factors pertinent to the post-treatment stage of
the process. For example, there may be a loss of positive verbal reinforcement from
staff and group members and an increase in unhelpful responses from GPs and
family members. Other factors beyond a person's control (eg. injury, illness,
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negative life events) may also contribute to the part reversal in treatment gains. The
question ofwho relapses and why (like the related work on prediction of adherence)
remains unclarified.
4.6.4. RELATIONSHIP BETWEEN RELAPSR AND SELF-EFFICACY
As hypothesized, post self-efficacy expectancies were found to be associated with
maintenance at 18 months, ie. there is further support for participants with higher
PSEQ and DSE after the course being more likely to maintain reductions in their
drug intake. Post-treatment self-efficacy was more closely associated with
maintenance when pre-treatment levels of drug intake were used to judge relapse.
This measure of maintenance incorporates more information about extent of relapse
and takes account of progress during the group. At post-treatment, PSEQ and DSE
are equally useful measures suggesting the quick, one item DSE score could be used
fruitfully at Time 2. Thus a general confidence in being able to perform activity
whilst in pain appears to be at least as important in maintaining drug reduction as
specific confidence in being able to cope with pain without medication. These
results emphasize the importance of finding methods during treatment to increase SE
in chronic pain patients.
There was support for the superiority of post-treatment SE compared to pre-
treatment SE as a predictor of maintenance. However, the current study failed to
find support for the use of pre-treatment PSEQ. Drug self-efficacy may be of some
use at this stage.
4.7. IMPLICATIONS FOR PRACTICE
Some suggestions ofways to improve the delivery of chronic pain management, and
the drug reduction regimen in particular, can be made on the basis of this study.
Adherence to drug reduction plans was associated with amount of drug reduction
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illustrating the importance of improving adherence. Some poor compliers did not
feel that paced reduction or time-controlled drug use was appropriate for them and
repetition of the rationale (perhaps by the PMP doctor) may be useful in such cases.
This study also identified a relationship between some cognitive variables and
adherence and/or drug reduction. This information could be used to help select
people at the start of treatment for work on drug reduction or, preferably, to target
those requiring extra support to increase their chances of success.
Attitudes and perceived barriers appear to be the most important TPB variables to
change to facilitate drug reduction. Unfortunately the AAH programme did not
succeed in altering attitudes (at least between the end of the medication education
session and the end of the programme). Further analysis to specify particular
attitudes for targeting would be helpful. The PMP was successful in reducing the
number of perceived barriers to drug reduction. However there is a suggestion that
sleeping difficulties, one of the most likely barriers to prevent reduction, would
benefit from more attention.
Current results suggest that pain self-efficacy is associated with adherence, drug
reduction and maintenance in line with other studies. Consequently, one of the most
important tasks for PMPs is to increase patients' confidence in their ability to use
strategies to manage pain and to reduce their drugs. Bandura (1986) discusses
methods for maximising SE. We are advised to focus on increasing patients' use of
ignoring pain sensations and coping self-statements (Keefe at al., 1997) and
encouraging attribution of this improvement to personal skills and abilities rather
than external factors (Dolce et al., 1986b). Matching different interventions to
different patients may be beneficial eg. intensive training in cognitive therapy
techniques might be especially helpful for patients prone to catastrophizing (Keefe et
al., 1997). Fortunately, measurement of SE is easy to perform. Re-assessing,
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perhaps midway through and at the end of the group, would highlight subjects who
could benefit from additional input.
A significant proportion (24 per cent) of participants failed to reduce their drugs at
all after planning to do so, illustrating a problem other than relapse. It may be that
this group were coerced into an action phase before they were ready. If so, more
time spent discussing the advantages of reducing initially may be useful in increasing
patients' motivation to work on drug reduction. Another 38 per cent of participants
who did make a reduction require more work on relapse prevention to facilitate
generalisation of treatment effects. Offering booster sessions is a strategy being
considered. Post-group drug self-efficacy (a single item) would be useful in
identifying patients who would benefit from such sessions. Finding ways of
changing unhelpful responses elicited from families and CPs remains a pressing
problem and more effort is required to discover what are the other important
influences in the patients' environments.
As drug reduction was not found to be a speedy process, it would seem more
appropriate at the AAH to aim for continued reduction post-treatment rather than
maintenance. Tackling reduction at this time may suit some (eg. who found
travelling to the group arduous). In fact, the initial stages of the programme may not
be the best time to target drug reduction when patients' view drugs as facilitating
group attendance and acquisition of coping strategies (which may in turn replace the
use of drugs). However, continued work post-treatment would require more detailed
long-term planning and, in some cases, GP involvement. Kerns, Bayer & Findley
(1999) suggest tailoring interventions based on an individual's SE and priorities for
change. They believe identifying one or two primary goals followed by stepwise
interventions may enhance SE and minimize information overload. Obviously, this
type of flexibility is more difficult to manage in a group format.
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Finally, on at least live occasions GPs introduced additional drugs or suggested dose
increases during the PMP. Improved liaison between the programme and GPs about
drug reduction is essential and these links are currently being developed. Ways of
dealing with conflicting advice could also be discussed with the patients.
Further clarification of the patients' goals and those of the programme in terms of
drug reduction is needed in order to devise clearer strategies.
4.8. IMPLICATIONS FOR FUTURE RESEARCH
A further important stage of the present study, given the present climate, would be to
calculate a cost-benefit analysis. Estimation of money saved in terms of cost of
drugs and possibly fewer GP appointments could be compared to the cost of the PMP
nurse's time.
Repetition of this study taking account of the highlighted weaknesses would be
useful. If a larger sample was employed it would be possible to analyse those that
opted out of drug reduction and efforts could be made to control for drug class and
pain diagnosis. In addition, more variables, such as prior experience of drug
reduction, could be examined. Finding a way of assessing Prochaska & Diclemente's
(1982) 'stage of change' prior to opting into reduction could be useful in identifying
those who seem to require more motivational work initially. The crucial role of self
efficacy was emphasized in this study. However, urgent research is warranted into
the variables which influence self-efficacy and the mechanisms mediating its effect.
Further research into which treatment strategies and method of reduction is best for
which patients is required. It could be that those patients who reduced little here
would have done better using the cocktail method. Self-change methods could also
be investigated by comparing a PMP group receiving drug reduction supervision with
a group receiving PMP minus supervised reduction. Those who were not on regular
medication were not investigated here. Many PMP attenders may have reduced
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successfully by themselves in the past and study of their attitudes and the methods
they employed could prove worthwhile.
This study did not investigate adherence to recommendations other than drug
reduction and little is known about how adherence to drug reduction covaries with
adherence to the other PMP regimens (eg. relaxation, exercise) during and after
treatment. Knowing which regimens are necessary and sufficient for change might
allow a reduction in the number and frequency of recommendations which should
improve adherence to the most important ones. Knowing the level of adherence
required for successful drug reduction would also be helpful.
Ultimately, research needs to focus less on simple outcome measures and more on
the processes of change to aid our understanding of who adheres (and relapses) and
why.
4.9. CONCLUSIONS
Some support was obtained for the Theory of Reasoned Action instead of the Theory
of Planned Behaviour. Attitudes and subjective norms were found to predict
intention to reduce drugs and favourable attitudes to drug reduction were associated
with actual amount reduced. Perceived barriers was the best single predictor of
amount reduced but the addition of attitudes into the multiple regression model
explained all of this variance. Oddly, negative intention was also associated with
drug reduction. The failure of the TPB to explain any of the variance in adherence to
drug reduction plans was attributed to the patient-controlled nature of drug reduction
enabling patients to make little progress whilst complying with their plans. The
overall failure to explain large amounts of the variance could be due to weaknesses
in the measurement of the TPB variables, adherence or drug reduction.
Alternatively, the TPB may have poor generalizability to this domain and other
models may be more useful. For instance, in keeping with previous research, self-
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efficacy was found to be related to adherence, drug reduction and maintenance and
other variables, not measured here, such as biological and pharmacological factors
are also likely to contribute.
As expected, follow-up data illustrated a trend towards relapse in drug reduction and
self-efficacy over 18 months but not back to pre-treatment levels. However, nearly a
quarter of participants never made any drug reduction, indicating a problem of
motivation rather than relapse. Adherence to plans was found to be important for
drug reduction during the group but nonadherence was not associated with relapse
thereafter. Pre and post treatment self-efficacy were related to relapse in drug
reduction at 1 and 18 months. To improve outcome it seems important to find
methods of increasing favourable attitudes to drug reduction, sel f-efficacy and
adherence to plans. These variables could be used by the PIMP to target individuals
for drug reduction intervention or to receive additional support.
Despite the lack of strong results, this study has highlighted some of the difficulties
of carrying out such research in the pain management field and produced some
suggestions for practice. Further adherence research is warranted in this area and
expansion of current models (eg. to include interactions between behavioural,
physiological and cognitive events) may make this task more fruitful.
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Introduction of exercise and stretching
Why being active is good for you
Over Activity Rest Cycle
Drugs and Pain









"How to move" Session 2
Lifting and movement
How do we feel pain?
Gate control theory and thresholds for pain
Show video
Adrenalin and arousal
How thinking influences pain
Introduce GSR machines
How thinking influences pain
Introduce Watches
Pain behaviour and dealing with families,
including assertion techniques.First Aid pack
How to set long term goals
Relapse prevention and dealing with
flare-ups
NAME:
DRUG REDUCTION QUESTIONNAIRE APPENDIX B
(LONG FORM!
This questionnaire contains general statements about your beliefs about reducing the drugs
you take for your pain. There are no right or wrong answers, I am interested in your views.
For each item, please circle one of the numbers on the line below the statement.
For example:
strongly 1 2 3 4 (T) 6 7 strongly
disagree agree
1. If I reduce my drugs, I will experience a lot more pain.
strongly J 2 3 4 5 6 7 strongly
disagree agree
2. If I reduce my drugs, my self-confidence will improve.
strongly j 2 3 4 5 6 7 strongly
disagree agree
3. If I reduce my drugs, I will feel that I am more in control of my pain on my own.
strongly 1 2 3 4 5 6 7 strongly
disagree agree
4. If I reduce my drugs, other people will think I am not really suffering pain.
strongly 1 2 3 4 5 6 7 strongly
disagree agree
5. If I reduce my drugs and then start taking more again, I will have failed with my
drugs.
strongly 1 2 3 4 5 6 7 strongly
disagree agree
6. If I reduce my drugs, I will feel more anxious.
strongly 1 2 3 4 5 6 7 strongly
disagree agree
7. If I reduce my drugs, I will have stopped taking things which are not helping my
pain.
strongly 1 2 3 4 5 6 7 strongly
disagree agree
8. If I reduce my drugs, I will lose the one thing that gives me some control over my
pain.
strongly 1 2 3 4 5 6 7 strongly
disagree agree
9. If I reduce my drugs, I will see my GP or Consultant less.




10. My current level of drugs causes me side-effects.
very 1 2 3 4 5 6 7 not at
allmuch
11. Is there anything else that might happen if you reduce your drugs?
12. For you personally, do you think the advantages of taking drugs for your pain
outweigh the disadvantages?
YES / NO (please delete)
13. Experiencing a lot more pain would be
extremely 1 2 3 4 5 6 7 extremely
bad good
14. An improvement in my self-confidence would be
extremely 1 2 3 4 5 6 7 extremely
bad good
15. Other people knowing that I am suffering pain would be
extremely 1 2 3 4 5 6 7 extremely
bad good
16. Feeling that I am more in control of my pain on my own would be
extremely 1 2 3 4 5 6 7 extremely
bad good
17. Failing with my drugs would be
extremely 1 2 3 4 5 6 7 extremely
bad good
18. Feeling more anxious would be
extremely 1 2 3 4 5 6 7 extremely
bad good
19. Stopping taking drugs which are not helping my pain would be
extremely 1 2 3 4 5 6 7 extremely
bad good
20. Losing the one thing that gives me some control over my pain would be
extremely 1 2 3 4 5 6 7 extremely
bad good
21. Seeing my GP or Consultant less would be
extremely 1 2 3 4 5 6 7 extremely
bad good
22. Being without side-effects would be
extremely 1 2 3 4 5 6 7 extremely
bad good
23. For me to reduce my drugs is
bad 1 2 3 4 5 6 7 good
24. For me to reduce my drugs is
harmful 1 2 3 4 5 6 7 beneficial
25. For me to reduce my drugs is
foolish J 2 3 4 5 6 7 wise
26. Organizing how I take my drugs is almost entirely up to me.
false \ 2 3 4 5 6 7 true
27. I am going to reduce my drugs.
extremely J 2 3 4 5 6 7 extremely
unlikely likely
28. If I reduce my drugs my family would
disapprove 1 2 3_ 4 5 6 7 approve
29. If I reduce my drugs my GP would
disapprove J 2 3 4 5 6 7 approve
30. If I reduce my drugs my Hospital Consultant (if applicable) would
disapprove 1 2 3 4 5 6 7 approve
31. It is mostly up to me whether or not I succeed in reducing my drugs,
false 1 2 3 4 5 6 7 true
32. I wish to do what my family thinks I should do.
not at 1 2 3 4 5 6 7 very
all much
33. I wish to do what my GP thinks I should do.
not at 1 2 3 4 5 6 7 very
all much
34. I wish to do what my Hospital Consultant (if applicable) thinks I should do.
not at i 2 3 4 5 6 7 very
all much
35. How likely are the following to prevent you from reducing your drugs?
a) Suffering a flare-up of pain.
prevent ] 2 3 4 5 6 7 not prevent
me me
b) Being under stress.
prevent 1 2 3 4 5 6 7 not prevent
me me
c) Feeling low in mood.
prevent 1 2 3 4 5 6 7 not prevent
me me
d) Suffering a new pain or injury.
prevent 1 2 3 4 5 6 7 not prevent
me me
e) Not being able to do as much.
prevent 1 2 3 4 5 6 7 not prevent
me me
f) Having little confidence in other strategies to help deal with your pain.
prevent 1 2 3 4 5 6 7 not prevent
me me
g) Having little time/energy to use other strategies.
prevent 1 2 3 4 5 6 7 not prevent
me me
h) Feeling uncertain about trying something new.
prevent 1 2 3 4 5 6 7 not prevent
me me
i) Being pressurized by your family to take your drugs.
prevent 1 2 3 4 5 6 7 not prevent
me me
j) Sleeping badly.
prevent 1 2 3 4 5 6 7 not prevent
me me
k) Suffering withdrawal effects.
prevent 1 2 3 4 5 6 7 not prevent
me me
1) Receiving conflicting advice from other medical staff.
prevent 1 2 3 4 5 6 7 not prevent
me me
36. Is there anything else which might stop you from reducing your drugs?
FOR READERS' ATTENTION
Qs. 1, 6, 8, 10, 13, 18 & 20 were scored by substituting 7 to 1 scale.
Qs. 28, 29 & 30 were scored by substituting a -3 to 3 scale.
Qs. 4, 5, 9, 15, 17 & 21 were excluded from attitude scores.
DRUG REDUCTION QUESTIONNAIRE APPENDIX C
fSHORT FORM)
NAME:
This questionnaire contains general statements about your beliefs about reducing the drugs
you take for your pain. There are no right or wrong answers, I am interested in your views.
For each item, please circle one of the numbers on the line below the statement.
For example:
strongly 1 2 3 4 (T) 6 7 strongly
disagree agree
1. If I reduce my drugs, I will experience a lot more pain.
strongly 1 2 3 4 5 6 7 strongly
disagree agree
2. If I reduce my drugs, my self-confidence will improve.
strongly J 2 3 4 5 6 7 strongly
disagree agree
3. If I reduce my drugs, I will feel that I am more in control of my pain on my own.
strongly 1 2 3 4 5 6 7 strongly
disagree agree
4. If I reduce my drugs, other people will think I am not really suffering pain.
strongly J 2 3 4 5 6 7 strongly
disagree agree
5. If I reduce my drugs and then start taking more again, I will have failed with my
drugs.
strongly 1 2 3 4 5 6 7 strongly
disagree agree
6. If I reduce my drugs, I will feel more anxious.
strongly J 2 3 4 _5 6 7 strongly
disagree agree
7. If I reduce my drugs, I will have stopped taking things which are not helping my
pain.
strongly ] 2 3 4 5 6 7 strongly
disagree agree
8. If I reduce my drugs, I will lose the one thing that gives me some control over my
pain.
strongly strongly
disagree ] 2 3 4 5 6 7 agree
9. If I reduce my drugs, I will see my GP or Consultant less.
strongly 1 2 3 4 5 6 7 strongly
disagree agree
10. My current level of drugs causes me side-effects.
very J 2 3 4 5 6 7 not at
much all
11. Was there anything else that happened when you tried to reduce your drugs?
12. For you personally, do you think the advantages of taking drugs for your pain
outweigh the disadvantages?
YES / NO (please delete)
13. For me to reduce my drugs is
bad 1 2 3 4 5 6 7 good
14. For me to reduce my drugs is
harmful 1 2 3 4 5 6 7 beneficial
15. For me to reduce my drugs is
foolish J 2 3 4 5 6 7 wise
16. Organizing how I take my drugs is almost entirely up to me.
false 1 2 3 4 5 6 7 true
17. It is mostly up to me whether or not I succeed in reducing my drugs,
false 1 2 3 4 5 6 7 true
18. How much did the following prevent you from reducing your drugs?
a) Suffering a flare-up of pain.
prevent J 2 3 4 5 6 _7 not prevent
me me
b) Being under stress.
prevent 1 2 3 4 5 6 7 not prevent
me me
c) Feeling low in mood.
prevent 1 2 3 4 5 6 7 not prevent
me me
d) Suffering a new pain or injury.
prevent 1 2 3 4 5 6 7 not prevent
me me
e) Not being able to do as much.
prevent 1 2 3 4 5 6 7 not prevent
me me
f) Having little confidence in other strategies to help deal with your pain.
prevent J 2 3 4 5 6 7 not prevent
me me
g) Having little time/energy to use other strategies.
prevent j 2 3 4 5 6 7 not prevent
me me
h) Feeling uncertain about trying something new.
prevent 1 2 3 4 5 6 7 not prevent
me me
i) Being pressurized by your family to take your drugs.
prevent J 2 3 4 5 6 7 not prevent
me me
j) Sleeping badly.
prevent 1 2 3 4 5 6 7 not prevent
me me
k) Suffering withdrawal effects.
prevent 1 2 3 4 5 6 7 not prevent
me me
1) Receiving conflicting advice from other medical staff.
prevent J 2 3 4 5 6 7 not prevent
me me
19. Was there anything else which stopped you from reducing your drugs?
20. How much support did you get on the course to help you reduce your drugs?
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NAME: DATE
Please rate how confident you are that you can do the following things at present,
despite the pain. To answer circle one of the numbers on the scale under each
item, where 0 = "Not at all confident" and 6 = "Completely confident"
FOR EXAMPLE:-
0 1 2 ; 3
Not at all Completely
Confident Confident
Remember, this questionnaire is not asking whether or not you have been doing
these things, but rather, how confident you are that you can do them at the
present, despite the pain.
1) I can still enjoy things, despite the pain.
0 _J 2 3 4 5 6
Not at all Completely
Confident Confident
2) I can still do most of the household chores (e.g. tidying up, washing
dishes etc.) despite the pain.
0 1 2 3 4 5 6
Not at all Completely
Confident Confident
3) 1 can socialise with my friends or family members as often as I used to,
despite the pain.
0 I 2 3 4 5 6
Not at all Completely
Confident Confident
4) I can cope with my pain in most situations.
0 1 2 3 4 5
. 6
Not at all Completely
Confident Confident
5) I can do some sort of work, despite the pain
("Work" includes housework, paid or unpaid work)
0 1 2 3 4
_ 5 6
Not at all Completely
Confident Confident
Turn over the page.
6) I can still do many of the things 1 enjoy doing, such as hobbies or
































CALCULATION OF MEASURES OF ADHERENCE
1, Days Method
Adherence = (No. of days adhere) / (No. of days working on plans) %
2. Pills Method
Adherence = (No. of deviations from plan over course) / (No. of planned pills over
course) %
Notes
1. It is acknowledged that patients may increase their medication when in flare-up
(ie. suffering more than their usual level of pain) and, ideally, patients should
negotiate a "flare-up plan". This would enable adherence with flare-up plans to be
measured. As flare-up plans were not negotiated early in treatment, days when
additional drugs were taken in flare-up had to be excluded from the total number of
days.
2. On several occasions GPs interfered with plans and subjects were scored as
adhering if they followed their GP's advice. This may not have been justified if the
patients had explicitly or implicitly suggested the medication change to their GPs
rather than, as the patients claimed, the doctor advised it.
3. Any deviation from the plan (eg. more planned or nonplanned tablets, less tablets)
was scored equally. Some may argue that taking less medication is not as serious as
taking more. However, the PMP advocates paced reduction on a time-controlled
basis. By taking less on some days drugs will continue to be reinforcing and
reducing too quickly may be more likely to lead to failure.
4. Any additional medications taken for other ailments were excluded from
calculations. Size of dose was used to determine whether antidepressants,
anticonvulsants and muscle relaxants had been prescribed for analgesia or other
purposes.
5. Adherence to the spread of drug intake throughout the day was measured when
the step of the plan involved changing from prn to time-contingent use. If the step
involved making a reduction, spread of drug intake throughout the day was not
assessed.
6. The plan to which adherence was being measured involved the abolition or
reduction of drug use. Substitution of other strategies (eg. relaxation, planning of
activity) was advocated as part of the Pain Management Programme but was not
measured as part of drug reduction plans.
CALCULATION OF MEASURE OF DRUG REDUCTION
(Change in dose over course) / (maximum daily dose*) calculated for individual
drugs. Proportions summed for those on >1 drug.
* provided by AAH pharmacist from the British National Formulary (BNF)
This measure was calculated (i) excluding days when additional drugs were taken in
flare-up and (ii) including such days.
REMARKS
Using the days method to measure adherence is rather crude in that on noncompliant
days the extent of the deviation from the plan is not calculated. This is accounted for
by the pills method. However, the pills method is influenced by the number of pills
someone is taking, ie. if someone is on 12 pills daily and takes an extra one this
contributes less to the adherence score as opposed to someone who is on one tablet
and takes an extra one (being unlikely to take an extra quarter tablet). Thus it may
be easier for the big pill takers to be compliant. Furthermore, it may be preferable to
use number of doses rather than the absolute number of pills to ealeulate this method
to cater for people taking two pills together (because of the size of pills).
The validity of the two methods of calculating adherence were supported by their
significant correlation. In addition, they appeared to be intuitively appropriate. It is
expected that using other self-report methods to calculate adherence would also
correlate.
The major difficulty in calculating drug reduction is that equivalence tables of
analgesic potency across different drug classes do not exist. Thus some of the drugs
may be easier or harder to reduce than others and this is not being fully controlled
for. Opiates might be considered the hardest and consideration was given to coding
subjects on these drugs until it transpired that all subjects were using opiates. Using
maximum daily doses for each drug is an attempt to control for some of the
pharmacological variance.
However, even if equivalence tables had been available their applicability for
chronic pain would be uncertain as they would be based on acute pain. Furthermore,
the varying responses of individuals and the interactions of different types of drugs
when taken together could not be controlled for. Obviously these are additional
problems with the method employed. If time and resources had permitted, an
alternative method would be to ask a small number of physicians to rank the various
drug combinations according to difficulty to reduce.
However, on discussion with medical and pharmacy colleagues it was felt to be
meaningful to calculate a measure of drug reduction across drug classes. Chronic
pain patients may be more "psychologically dependent" on their drugs meaning that
any reduction would be equally difficult. Feelings of control, hope, etc. are common
across drug classes and require to be given up on reduction. However, these results
should be interpreted with caution due to the inability to completely control for
analgesic potency.
The measure of drug reduction involved adding the reduction proportions of each
drug, if someone was taking more than one compound. Therefore it could be argued
that someone who is on more drugs has a greater opportunity to reduce. An
alternative method would be to use the average reduction proportion for each drug in
an attempt to control for opportunity. However, as drug reduction is recommended
to be done one drug at a time, the averaging method would penalize someone who
had targeted one drug but in the short time span of the group had not reduced the
others. Opportunity to reduce may be less of a problem than anticipated as people
were not generally running out of drugs to reduce! Only three subjects had reduced
completely by stopping instantly and one had done this with two drugs
simultaneously. Finally, adherence scores were calculated on the basis of adherence
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APPENDIX H
TableAl: Results ofMultiple Regression Analyses
Multiple Regression Analysis of Intention
Step R Sqd Adj R Sqd Predictor beta T sig T
1. 0.70 0.65 Attitudes 0.67 4.55 0.00***
Subjective Norms 0.28 2.18 0.04*
PBC 0.15 1.30 0.21
Perceived Barriers -0.29 -0.21 0.84
Multiple Regression Analysis of Compliance
Step R Sqd Adj R Sqd Predictor beta T sig T
1. 0.04 0.01 Intention 0.21 1.07 0.29
















Multiple Regression Analysis of Drug Reduction
Step R Sqd Adj R Sqd Predictor beta T sig T
1. 0.00 -0.03 Intention 0.65 0.33 0.74

















Histogram of compliance scores (days method)
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Many chronic pain patients are prescribed tablets which are a standardized
mixture of opiates, anti-inflammatories or Paracetamol. Common examples are
Co-proxamol, Co-dydramol and Co-codamol with Co-codamol tablets, for
instance, being comprised of 8mg Codeine Phosphate and 500mg Paracetamol.
Prescribed dose is simply 'number of tablets per day' with a maximum daily dose
of 8 tablets for all compound analgesics being consumed by participants in this
study.
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AAH - Astley Ainslie Hospital
PMP - Pain Management Programme
PCR - Patient-Controlled Reduction
TRA - Theory of Reasoned Action
TP6 - Theory of Planned Behaviour
PBC - Perceived Behavioural Control
HBM - Health Belief Model
SE Self-Efficacy
PSEQ - Pain Self-Efficacy Questionnaire
DSE - Drug Self-Efficacy (Q7 of PSEQ)
HADS - Hospital Anxiety and Depression Scale
BDI - Beck Depression Inventory
Time 1 - Pre drug reduction work
Time 2- End of programme
Time 3- 1 month follow-up
Time 4- 18 month follow-up
